Brain Scientific (BRSF) S-1/A 14 Feb 23 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2022
Document Information Line Items
Entity Registrant Name	BRAIN SCIENTIFIC INC.
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 3
Entity Central Index Key	0001662382
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash	$ 2,029,839	$ 785,363	$ 68,943
Accounts receivable	5,971	16,922
Inventory	126,132	146,090	44,904
Advances to officers		16,941	7,542
Prepaid expenses and other current assets	290,795	166,458	12,000
TOTAL CURRENT ASSETS	2,452,737	1,131,774	133,389
Property and equipment, net	124,740	122,979	91,742
Intangible assets, net	10,343,538	10,920,577
Goodwill	913,184	913,184
Operating lease right-of-use asset	107,617	191,702
Long-term prepaid insurance	80,000	95,000
TOTAL ASSETS	14,021,816	13,375,216	225,131
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,653,036	2,987,264	1,444,476
Accounts payable and accrued expenses - related party (Accrued director’s fees)	75,000	75,000
Accrued interest	172,407	356,998	26,766
Convertible notes payable, net	1,912,523	337,000
Notes payable		320,000	650,000
Loans payable	6,667	6,667
Notes payable - related party	47,998	155,989
Derivative liabilities	1,857,351
Operating lease liability, current portion	81,012	104,591
TOTAL CURRENT LIABILITIES:	6,805,994	4,343,509
Convertible notes payable, net		9,635,551
Operating lease liability, net of current portion	29,150	91,089
Paycheck protection program (PPP) loan			111,477
TOTAL LIABILITIES	6,835,144	14,070,149	2,232,719
Commitments and contingencies – Note 17
Preferred stock
Common stock	1,240	591	347
Additional paid in capital	38,578,689	21,587,389	11,170,302
Accumulated deficit	(31,389,283)	(22,278,923)	(13,178,237)
Accumulated other comprehensive loss	(3,974)	(3,990)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	7,186,672	(694,933)	(2,007,588)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 14,021,816	13,375,216	225,131
Previously Reported
CURRENT LIABILITIES:
TOTAL CURRENT LIABILITIES:		4,006,509	2,121,242
Convertible notes payable, net		$ 9,972,551

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	1,240,094	590,857	347,333
Common stock, shares outstanding	1,240,094	590,857	347,333
Previously Reported [Member]
Common stock, shares authorized		200,000,000	200,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
REVENUE	$ 11,432	$ 5,275	$ 209,484	$ 14,482	$ 265,747	$ 93,664
COST OF GOODS SOLD	4,058	4,143	148,701	7,840	182,519	43,762
GROSS PROFIT	7,374	1,132	60,783	6,642	83,228	49,902
SELLING, GENERAL AND ADMINISTRATIVE
Research and development	56,684	48,282	224,405	147,324	329,452	210,706
Professional fees	94,014	247,423	538,188	573,309	818,698	268,223
Sales and marketing expenses	165,414	260,832	570,666	498,583	1,041,575	197,372
Share based compensation	2,625,571		3,204,382		3,223,674	311,919
General and administrative expenses	1,083,778	1,177,077	3,628,337	2,292,775	3,326,306	1,831,170
TOTAL SELLING, GENERAL AND ADMINISTRATIVE	4,025,461	1,733,614	8,165,978	3,511,991	8,739,705	2,819,390
LOSS FROM OPERATIONS	(4,018,087)	(1,732,482)	(8,105,195)	(3,505,349)	(8,656,477)	(2,769,488)
OTHER INCOME (EXPENSE):
Interest expense	(703,232)	(68,357)	(2,589,486)	(182,574)	(467,849)	(29,474)
Amortization of debt discount					(89,787)
Loss on disposal of assets						(4,067)
Other income	347		7,252		1,110
Gain on forgiveness of paycheck protection loan				112,338	112,338
Change in fair market value of derivative liabilities	284,289		1,375,048
Gain on settlement of derivatives			201,097
Foreign currency transaction gain (loss)	(70)		924		(21)
TOTAL OTHER EXPENSE	(418,666)	(68,357)	(1,005,165)	(70,236)	(444,209)	(33,541)
LOSS BEFORE INCOME TAXES	(4,436,753)	(1,800,839)	(9,110,360)	(3,575,585)	(9,100,686)	(2,803,029)
PROVISION FOR INCOME TAXES
NET LOSS	(4,436,753)	(1,800,839)	(9,110,360)	(3,575,585)	(9,100,686)	(2,803,029)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment	1,338		16		(3,990)
TOTAL COMPREHENSIVE LOSS	$ (4,435,415)	$ (1,800,839)	$ (9,110,344)	$ (3,575,585)	$ (9,104,676)	$ (2,803,029)
NET LOSS PER COMMON SHARE
Net loss per common share, basic (in Dollars per share)	$ (3.58)	$ (5.18)	$ (10.68)	$ (10.29)	$ (25.22)	$ (8.88)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Weighted average number of common shares outstanding, basic (in Shares)	1,240,094	347,333	853,133	347,333	360,944	315,529

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net loss per common share, diluted	$ (3.58)	$ (5.18)	$ (10.68)	$ (10.29)	$ (25.22)	$ (8.88)
Weighted average number of common shares outstanding, diluted	1,240,094	347,333	853,133	347,333	360,944	315,529

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock	Series B Preferred Stock	Series C Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balances at Dec. 31, 2019	$ 96	$ 84	$ 175	$ 265	$ 10,408,624	$ (10,375,208)		$ 34,036
Balances (in Shares) at Dec. 31, 2019	95,518	83,707	175,066	265,164
Sale of Series C Preferred Stock			$ 3		53,461			53,464
Sale of Series C Preferred Stock (in Shares)			2,762
Warrants issued in connection with the sale of Series C Preferred Stock					46,536			46,536
Issuance of common stock for director services				$ 7	34,098			34,105
Issuance of common stock for director services (in Shares)				7,251
Recapitalization at reverse merger - May 20, 2020	$ (96)	$ (84)	$ (178)	$ 73	618,135			617,850
Recapitalization at reverse merger - May 20, 2020 (in Shares)	(95,518)	(83,707)	(177,828)	72,906
Issuance of common stock for services				$ 2	9,448			9,450
Issuance of common stock for services (in Shares)				2,012
Net loss						(2,803,029)		(2,803,029)
Balances at Dec. 31, 2020				$ 347	11,170,302	(13,178,237)		(2,007,588)
Balances (in Shares) at Dec. 31, 2020				347,333
Net loss						(654,004)		(654,004)
Balances at Mar. 31, 2021				$ 347	11,170,302	(13,832,241)		(2,661,592)
Balances (in Shares) at Mar. 31, 2021				347,333
Balances at Dec. 31, 2020				$ 347	11,170,302	(13,178,237)		(2,007,588)
Balances (in Shares) at Dec. 31, 2020				347,333
Net loss								(3,575,585)
Balances at Sep. 30, 2021				$ 347	11,170,302	(16,753,822)		(5,583,173)
Balances (in Shares) at Sep. 30, 2021				347,333
Balances at Dec. 31, 2020				$ 347	11,170,302	(13,178,237)		(2,007,588)
Balances (in Shares) at Dec. 31, 2020				347,333
Net loss								(9,100,686)
Balances at Dec. 31, 2021				$ 591	21,587,389	(22,278,923)	(3,990)	(694,933)
Balances (in Shares) at Dec. 31, 2021				590,857
Balances at Mar. 31, 2021				$ 347	11,170,302	(13,832,241)		(2,661,592)
Balances (in Shares) at Mar. 31, 2021				347,333
Net loss						(1,120,742)		(1,120,742)
Balances at Jun. 30, 2021				$ 347	11,170,302	(14,952,983)		(3,782,334)
Balances (in Shares) at Jun. 30, 2021				347,333
Net loss						(1,800,839)		(1,800,839)
Balances at Sep. 30, 2021				$ 347	11,170,302	(16,753,822)		(5,583,173)
Balances (in Shares) at Sep. 30, 2021				347,333
Net loss						(3,575,585)		(3,575,585)
Recapitalization October 1, 2021				$ 244	7,193,414			7,193,658
Recapitalization October 1, 2021 (in Shares)				243,400
Fair value of stock options and warrants vested					2,943,499			2,943,499
Issuance of common stock for services					280,174			280,174
Issuance of common stock for services (in Shares)				124
Foreign currency translation adjustment							(3,990)	(3,990)
Net loss						(5,525,101)		(5,525,101)
Balances at Dec. 31, 2021				$ 591	21,587,389	(22,278,923)	(3,990)	(694,933)
Balances (in Shares) at Dec. 31, 2021				590,857
Fair value of stock options vested					235,690			235,690
Issuance of common stock for services				$ 4	129,846			129,850
Issuance of common stock for services (in Shares)				4,243
Foreign currency translation adjustment							451	451
Net loss						(2,159,938)		(2,159,938)
Balances at Mar. 31, 2022				$ 595	21,952,925	(24,438,861)	(3,539)	(2,488,880)
Balances (in Shares) at Mar. 31, 2022				595,100
Balances at Dec. 31, 2021				$ 591	21,587,389	(22,278,923)	(3,990)	(694,933)
Balances (in Shares) at Dec. 31, 2021				590,857
Net loss								(9,110,360)
Balances at Sep. 30, 2022				$ 1,240	38,578,689	(31,389,283)	(3,974)	7,186,672
Balances (in Shares) at Sep. 30, 2022				1,240,094
Balances at Mar. 31, 2022				$ 595	21,952,925	(24,438,861)	(3,539)	(2,488,880)
Balances (in Shares) at Mar. 31, 2022				595,100
Fair value of stock options vested					280,510			280,510
Conversion of convertible debt into common shares				$ 645	13,719,683			13,720,328
Conversion of convertible debt into common shares (in Shares)				644,994
Foreign currency translation adjustment							(1,773)	(1,773)
Net loss						(2,513,669)		(2,513,669)
Balances at Jun. 30, 2022				$ 1,240	35,953,118	(26,952,530)	(5,312)	8,996,516
Balances (in Shares) at Jun. 30, 2022				1,240,094
Fair value of stock options vested					2,625,571			2,625,571
Foreign currency translation adjustment							1,338	1,338
Net loss						(4,436,753)		(4,436,753)
Balances at Sep. 30, 2022				$ 1,240	$ 38,578,689	$ (31,389,283)	$ (3,974)	$ 7,186,672
Balances (in Shares) at Sep. 30, 2022				1,240,094

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,110,360)	$ (3,575,585)	$ (9,100,686)	$ (2,803,029)
Change in net loss to net cash used in operating activities:
Depreciation and amortization expense	602,744	19,736	219,833	17,353
Amortization of debt discount and non-cash interest expense	1,892,418		89,787
Change in fair market value of derivative liabilities	(1,375,048)
Amortization of right of use asset		1,685
Gain on forgiveness of paycheck protection loan		(112,338)	(112,338)
Loss on disposal of assets			71,872	4,067
Gain on settlement of lease	(1,660)
Fair value of stock options vested	3,204,382		2,943,499	355,534
Common stock issued for services			280,174
Other long-term assets			(95,000)
Accounts receivable	10,951	(2,529)	(1,570)
Due from related parties		(43,423)
Inventory	19,958	(62,239)	(99,372)	(44,904)
Advances to officers	16,941	1,060	(9,399)	(5,559)
Prepaid expenses and other current assets	(124,337)	(33,511)	(95,920)	9,950
Long-term prepaid insurance	15,000
Accounts payable and accrued expenses	(195,489)	833,008	112,504	1,508,158
Accrued interest	553,677	182,575		26,766
Operating lease liabilities, net	227		(70,176)
Gain on debt extinguishment	(201,097)
Changes in operating assets and liabilities:
NET CASH USED IN OPERATING ACTIVITIES	(4,691,693)	(2,791,561)	(5,866,792)	(931,664)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for notes receivable		(603,067)
Purchase of property and equipment	(27,466)	(38,339)	(58,647)	(30,371)
NET CASH USED IN INVESTING ACTIVITIES	(27,466)	(641,406)	(58,647)	(30,371)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable, net of issuance costs	6,421,610
Proceeds from convertible notes payable			3,750,000
Proceeds from note payable		3,469,982	3,469,982	650,000
Proceeds from issuance of Series C Preferred Stock				100,000
Proceeds from PPP Loan				111,477
Repayment of promissory note			(574,133)
Repayment of related party loan	(53,000)
Repayment of convertible note payable	(30,000)
Repayment of promissory note and interest	(320,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,018,610	3,469,982	6,645,849	861,477
Effect of exchange rate changes on cash	(54,975)		(3,990)
NET CHANGE IN CASH	1,244,476	37,015	716,420	(100,558)
CASH AT BEGINNING OF THE PERIOD	785,363	68,943	68,943	169,501
CASH AT END OF THE PERIOD	2,029,839	105,958	785,363	68,943
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	106,039		72,000
Cash paid for taxes
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Intangible assets recorded at acquisition			11,113,000
Goodwill recognized at acquisition			913,184
Shares issued for acquisition			7,240,229
Net assets assumed in merger			(1,193,499)
Convertible notes payable assumed at merger			2,451,641
Notes payable converted into convertible notes payable			4,119,982
Notes payable assumed in merger			320,000
Accrued interest converted into convertible notes payable			$ 208,425
Accounts payable settled with share issuance	129,850
Services received settled with derivative warrants	156,399
Convertible notes payable and accrued interest converted to common shares	$ 13,921,427

Organization and Nature of Oper

Organization and Nature of Operations	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization and Nature of Operations [Abstract]
ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Brain Scientific Inc. (the “Company”), was incorporated under the laws of the state of Nevada on November 18, 2013 under the name All Soft Gels Inc. On October 1, 2021, the Company acquired Piezo Motion Corp (“Piezo”), a privately held Delaware corporation formed in January 2020. Upon completion of the acquisition, Piezo is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Piezo. The Company has two lines of operations The MemoryMD subsidiary group is involved in cloud computing, data analytics and medical device technology in the NeuroTech and brain monitoring industries seeking to commercialize its EEG devices and caps. The Piezo subsidiary group is focused on the ultrasonic standing wave-type piezo motor technology for rotary and linear motion and has experience in the research and development, as well as the manufacturing, of piezo motors for high-tech industries across the globe. The Company is headquartered in Sarasota, Florida. Reverse Merger and Corporate Restructure On June 11, 2021, the Company entered into a merger agreement (the “Merger Agreement”) with Piezo and BRSF Acquisition Inc. to acquire Piezo (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on October 1, 2021 and, pursuant to the terms of the Merger Agreement, all outstanding shares of Piezo were exchanged for 347,333 shares of the Company’s common stock and Piezo became the Company’s wholly owned subsidiary. The Merger was effected pursuant to the Merger Agreement. The Merger is being accounted for as a reverse merger whereby Piezo is the acquirer for accounting purposes. Piezo is considered the acquiring company for accounting purposes as upon completion of the Merger, Piezo’s former stockholders held a majority of the voting interest of the combined company. Pursuant to the Merger, the Company issued shares of its common stock to Piezo’s stockholders, at an exchange ratio of 0.03 shares of the Company’s common stock. All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented. Acquisition Accounting The fair value of Brain Scientific assets acquired and liabilities assumed was based upon management’s estimates assisted by an independent third-party valuation firm. The following table summarizes the allocation of purchase price of the acquisition:  Allocation Tangible Assets Acquired: Net working capital $ (1,186,622 ) Right of use asset 40,093 Lease liability (46,970 ) Net Tangible Assets Acquired $ (1,193,499 ) Intangible Assets Acquired: Licenses and trademarks Brain Scientific Trade Name 133,000 MemoryMD Trade Name 504,000 NeuroCap Trade Name 188,000 Neuro EEG Trade Name 11,000 Patent products NeuroCap Developed Technology 10,242,000 NeuroEEG Developed Technology 35,000 Net Intangible Assets Acquired $ 11,113,000 Total Fair Value of Assets Acquired $ 9,919,501 Consideration: Fair value of equity received 7,240,222 Liabilities assumed 2,987,152 Loans forgiven 605,311 Total consideration $ 10,832,685 Goodwill $ 913,184 Unaudited Interim Financial Information The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These consolidated financial statements are unaudited and, in the Company’s opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of its balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2021. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes.	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Brain Scientific Inc. (the “Company”), was incorporated under the laws of the state of Nevada on November 18, 2013 under the name All Soft Gels Inc. On October 1, 2021, the Company acquired Piezo Motion Corp (“Piezo”), a privately held Delaware corporation formed in January 2020. Upon completion of the acquisition, Piezo is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Piezo. The Company has two lines of operations The MemoryMD subsidiary group is involved in cloud computing, data analytics and medical device technology in the NeuroTech and brain monitoring industries seeking to commercialize its EEG devices and caps. The Piezo subsidiary group is focused on the ultrasonic standing wave-type piezo motor technology for rotary and linear motion and has experience in the research and development, as well as the manufacturing, of piezo motors for high-tech industries across the globe. The Company is headquartered in Sarasota, Florida. Reverse Merger and Corporate Restructure On June 11, 2021, the Company entered into a merger agreement (the “Merger Agreement”) with Piezo and BRSF Acquisition Inc. to acquire Piezo (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on October 1, 2021 and, pursuant to the terms of the Merger Agreement, all outstanding shares of Piezo were exchanged for 347,333 shares of the Company’s common stock and Piezo became the Company’s wholly owned subsidiary. The Merger was effected pursuant to the Merger Agreement. The Merger is being accounted for as a reverse merger whereby Piezo is the acquirer for accounting purposes. Piezo is considered the acquiring company for accounting purposes as upon completion of the Merger, Piezo’s former stockholders held a majority of the voting interest of the combined company. Pursuant to the Merger, the Company issued shares of its common stock to Piezo’s stockholders, at an exchange ratio of 0.03 shares of the Company’s common stock. Acquisition Accounting The fair value of Brain Scientific assets acquired and liabilities assumed was based upon management’s estimates assisted by an independent third-party valuation firm. The following table summarizes the allocation of purchase price of the acquisition:  Tangible Assets Acquired:   Allocation Net working capital (1,186,622 ) Right of use asset 40,093 Lease liability (46,970 ) Net Tangible Assets Acquired $ (1,193,499 )   Intangible Assets Acquired: Brain Scientific Trade Name 133,000 MemoryMD Trade Name 533,000 Neurocap Trade Name 188,000 Neuro EEG Trade Name 11,000 Customer Relationships (29,000 ) NeuroCap Developed Technology 10,242,000 NeuroEEG Developed Technology 35,000 Total Fair Value of Assets Acquired $ 11,113,000   Consideration: Fair value of equity received 7,240,222 Liabilities assumed 2,978,152 Loans forgiven 605,311 Goodwill $ 913,184

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Reverse Stock Split In connection with preparing for its share offering, the Company effected a one-for-85 reverse stock split of the Company’s common stock. The reverse stock split became effective on February 3, 2023. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share amounts in the financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The financial statements have also been retroactively adjusted to reflect adjustments to the amounts and conversion prices for convertible debt, stock options and warrants affected in connection with the reverse stock split. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its subsidiaries, Piezo Motion Corp, Discovery Technology International, Inc., MemoryMD US, MemoryMD – Russia and MemoryMD - Europe. All significant consolidated transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants. The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time. Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At September 30, 2022 and December 31, 2021, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of September 30, 2022, and December 31, 2021, the Company had $1,621,012 and $277,989, respectively, in excess over the FDIC insurance limit. I nventory Inventory consists of raw material, works in progress and finished goods that are valued at lower of cost or market using the weighted average method. Property and Equipment Property, plant and equipment are carried at cost. Depreciation is provided on the straight-line method over the assets estimated service lives. Expenditures for maintenance and repairs are charged to expense in the period in which they are incurred, and betterments are capitalized. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are reflected in the accompanying statements of operations of the respective period. The estimated useful lives range from 3 to 7 years. Intangible assets, net Intangible assets are measured at cost less accumulated amortization and impairment losses, if any. Intangible assets are amortized on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Patents 15 years Licenses and trademarks 9 years Amortization expense is included in the consolidated income statement within general and administrative expenses. The asset is tested annually and during interim periods for impairment if there is a trigger for impairment. Good will Goodwill represents the excess of the consideration transferred over the fair value of the net identifiable assets acquired. Goodwill is evaluated for impairment annually or whenever we identify certain triggering events or circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include, among other things, unexpected adverse business conditions, macro and reporting unit specific economic factors (for example, interest rate and foreign exchange rate fluctuations, and loss of key personnel), supply costs, unanticipated competitive activities, and acts by governments and courts. Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be at a discount to the common stock at the time of conversion. For certain notes, the conversion features are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred. Revenue Recognition The Company recognizes revenue under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, (“ASC 606”). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract  ● Step 3: Determine the transaction price   ● Step 4: Allocate the transaction price to the performance obligations in the contract   ● Step 5: Recognize revenue when the Company satisfies a performance obligation   In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606’s definition of a “distinct” good or service (or bundle of goods or services) if both of the following criteria are met: The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct), and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). The Company has determined that product delivery is the primary performance obligation, and as such recognizes revenues upon delivery to the customer. If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. When determining the transaction price, an entity must consider the effects of all of the following: ● Variable consideration   ● Constraining estimates of variable consideration   ● The existence of a significant financing component in the contract   ● Noncash consideration   ● Consideration payable to a customer   Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate. The Company recognizes revenue from the sale of NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. Primarily all revenues for the nine months ended September 30, 2022 are from the sale of medical devices purchased from Neurotech. Revenues for the nine months ended September 30, 2021 of $14,482 related to the sales of Piezo evaluation kits. Research and Development Costs The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the three and nine months ended September 30, 2022 were $56,684 and $224,405, respectively. Research and development costs recognized in the statement of operations for the three and nine months ended September 30, 2021 were $48,282 and $147,324, respectively. Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the three and nine months ended September 30, 2022 were $165,414 and $570,666, respectively. Advertising and marketing costs recognized in the statement of operations for the three and nine months ended September 30, 2021 were $260,832 and $498,583, respectively. Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the three and nine months ended September 30, 2022 and 2021, 1,873,406, and 0 anti-dilutive securities were excluded from the computation, respectively. Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. As of September 30, 2022, the Company had a Level 3 financial instrument related to the derivative liabilities related to the issuance of convertible debt and warrants. The Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2021. Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of September 30, 2022. Liabilities Amounts Level 1 Level 2 Level 3 Derivative liability – conversion feature $ 1,159,000 $ - $ - $ 1,159,000 Derivative liability – warrants 698,351 - - 698,351 Total $ 1,857,351 $ - $ - $ 1,857,351 Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of September 30, 2022, and December 31, 2021, the Company had no unrecognized uncertain income tax positions. Reclassification Certain prior years balances have been reclassified to conform to current year presentation. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Reverse Stock Split In connection with preparing for its share offering, the Company effected a one-for-85 reverse stock split of the Company’s common stock. The reverse stock split became effective on February 3, 2023. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share amounts in the financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The financial statements have also been retroactively adjusted to reflect adjustments to the amounts and conversion prices for convertible debt, stock options and warrants affected in connection with the reverse stock split. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its subsidiaries, Piezo Motion Corp, Discovery Technology International, Inc., MemoryMD US, MemoryMD – Russia and MemoryMD - Europe. All significant consolidated transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants. The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time. Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2021 and December 31, 2020, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of December 31, 2021 and December 31, 2020, the Company had $277,989 and $0, respectively, in excess over the FDIC insurance limit. I nventory Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method. Property and Equipment Property, plant and equipment are carried at cost. Depreciation is provided on the straight-line method over the assets estimated service lives. Expenditures for maintenance and repairs are charged to expense in the period in which they are incurred, and betterments are capitalized. The cost of assets sold or abandoned and the related accumulated depreciation are eliminated from the accounts and any gains or losses are reflected in the accompanying statements of operations of the respective period. The estimated useful lives range from 3 to 7 years. Goodwill Goodwill represents the excess of the consideration transferred over the fair value of the net identifiable assets acquired. Goodwill is evaluated for impairment annually or whenever we identify certain triggering events or circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include, among other things, unexpected adverse business conditions, macro and reporting unit specific economic factors (for example, interest rate and foreign exchange rate fluctuations, and loss of key personnel), supply costs, unanticipated competitive activities, and acts by governments and courts. Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be a discount to the common stock at the time of conversion. Some of the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred. Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. All revenue for the years ended December 31, 2021 and 2020 is from the sale of medical devices purchased from Neurotech, a related party. Research and Development The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the years ended December 31, 2021 and 2020 were $329,452 and $210,706, respectively. Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the years ended December 31, 2021 and 2020 were $1,041,575 and $197,372, respectively. Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the years ended December 31, 2021 and 2020, 84,193 and 0, respectively, of anti-dilutive securities were excluded from the computation. Reclassification Certain prior years balances have been reclassified to conform to current year presentation. Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2021 and 2020. Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of December 31, 2021, and December 31, 2020, the Company had no unrecognized uncertain income tax positions. Recent Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its consolidated financial statements.

Going Concern

Going Concern	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Going Concern [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern for a period of one year from the issuance of these financial statements. For the nine months ended September 30, 2022, the Company had $209,484 in revenues, a net loss of $9,110,360 and had net cash used in operations of $4,691,693. Additionally, as of September 30, 2022, the Company had an accumulated deficit and negative working capital of $31,389,283 and $4,353,257, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of the issuance of these financial statements. The financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications and ultimately achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investments or achieve an adequate sales level.	NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern for a period of one year from the issuance of these financial statements. For the year ended December 31, 2021, the Company had $265,747 in revenues, a net loss of $9,100,686 and had net cash used in operations of $5,794,792. Additionally, as of December 31, 2021, the Company had working capital deficit, stockholders’ deficit and accumulated deficit of $2,874,735, $694,933 and $22,278,923, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of the issuance of these financial statements. The financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications and ultimately achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investments or achieve an adequate sales level.

Inventory

Inventory	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Inventory [Abstract]
INVENTORY	NOTE 4 – INVENTORY September 30, December 31, Raw materials $ 76,379 $ 93,190 Works in progress 11,911 11,857 Finished goods 37,842 41,043 Total $ 126,132 $ 146,090	NOTE 4 – INVENTORY December 31, December 31, Raw materials $ 93,190 $ 20,608 Parts 11,857 2,349 Finished goods 41,043 21,947 Total $ 146,090 $ 44,904

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 5 – PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, December 31, Prepaid Expenses $ 145,734 $ - Prepaid insurance 119,331 105,900 Other prepaid expenses 11,352 46,170 Lease deposits 14,378 14,378 Other assets - 10 Total $ 290,795 $ 166,458 As of September 30, 2022 and December 31, 2021, there was a total amount of $80,000 and $95,000 of long-term prepaid insurance, respectively.	NOTE 5 – PREPAID EXPENSES AND OTHER CURRENT ASSETS December 31, December 31, Prepaid insurance $ 105,900 $ - Other prepaid expenses 46,170 7,000 Lease deposits 14,378 5,000 Other assets 10 - Total $ 166,458 $ 12,000 As of December 31, 2021 and 2020, there was a total amount of $95,000 and $0 of long-term prepaid insurance, respectively.

Property and Equipment

Property and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: September 30, December 31, Machinery and equipment $ 204,143 $ 176,678 Leasehold improvements 12,283 12,283 216,426 188,961 Less: Accumulated depreciation (91,686 ) (65,982 ) Total $ 124,740 $ 122,979 Depreciation expense was $8,635 and $25,704 for the three and nine months ended September 30, 2022, respectively. Depreciation expense was $7,538 and $19,376 for the three and nine months ended September 30, 2021, respectively.	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: December 31, December 31, Computer equipment $ - $ 4,164 Machinery and equipment 176,678 121,433 Leasehold improvements 12,283 5,000 188,961 130,597 Less: Accumulated depreciation (65,982 ) (38,855 ) Total $ 122,979 $ 91,742 Depreciation expense was $27,410 and $17,353 for the year ended December 31, 2021 and 2020, respectively.

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Intangible Assets, Net [Abstract]
INTANGIBLE ASSETS, NET	NOTE 7 – INTANGIBLE ASSETS, NET The components of the acquired intangible assets were as follows: September 30, December 31, Average Patent products $ 10,277,000 $ 10,277,000 15.4 Licenses and trademarks 836,000 836,000 9 Intangible assets $ 11,113,000 $ 11,113,000 Less: Accumulated amortization (769,462 ) (192,423 ) Total $ 10,343,538 $ 10,920,577 Amortization expense was $192,365 and $577,039 for the three and nine months ended September 30, 2022, respectively. There was no	NOTE 7 – INTANGIBLE ASSETS, NET Pursuant to the Merger, the Company accounted for the transaction as a reverse acquisition as prescribed in Accounting Standards Codification 805, Business Combinations (“ASC 805”) and ASC 820 – Fair Value Measurements and Disclosures (“ASC 820”). The following table summarizes the allocation of purchase price of the acquisition: Tangible Assets Acquired: Allocation  Net working capital $ (1,186,622 ) Right of use asset 40,093 Lease liability (46,970 ) Net Tangible Assets Acquired $ (1,193,499 )        Intangible Assets Acquired:      Brain Scientific trade name $ 133,000 MemoryMD trade name 533,000 NeuroCap trade name 188,000 NeuroEEG trade name 11,000 Customer relationships (29,000 ) NeuroCap developed technology 10,242,000 NeuroEEG developed technology 35,000 Total Fair Value of Assets Acquired $ 11,113,000        Consideration:      Fair value of equity received 7,240,222 Liabilities assumed 2,978,152 Loans forgiven 605,311 Goodwill $ 913,184 The components of the acquired intangible assets were as follows:   Preliminary     Average   Fair   Estimated Life Patent products $  10,277,000 3.3 - 15.4 Licenses and trademarks   865,000 9 Customer/distribution list   (29,000) 12.5 $ 11,113,000     Accumulated amortization (192,423 ) Total 10,920,577

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable as of September 30, 2022 and December 31, 2021 consisted of the following: September 30, December 31, Trade payables $ 1,143,649 $ 1,101,028 Accrued payroll and related expenses 1,380,194 1,593,925 Accrued expenses 122,311 255,820 Customer deposits 6,882 36,491 Total $ 2,653,036 $ 2,987,264	NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable as of December 31, 2021 and 2020 consisted of the following: December 31, December 31, Trade payables $ 1,101,028 $ 398,155 Accrued payroll and related expenses 1,593,925 997,410 Accrued expenses 255,820 48,911 Customer deposits 36,491 - Total $ 2,987,264 $ 1,444,476

Accrued Director's fees

Accrued Director's fees	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accrued director's fees [Abstract]
ACCRUED DIRECTOR’S FEES	NOTE 9 – ACCRUED DIRECTOR’S FEES Accounts payable related parties as of September 30, 2022 and December 31, 2021 consists of accrued director’s fees in the amount of $75,000.	NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES – RELATED PARTY Accounts payable related parties as of December 31, 2021 consists of accrued director’s fees in the amount of $75,000. There was no balance at December 31, 2020.

Convertible Notes Payable _ Sho

Convertible Notes Payable – Short Term	9 Months Ended
	Sep. 30, 2022
Convertible Notes Payable Short Term [Abstract]
CONVERTIBLE NOTES PAYABLE – SHORT TERM	NOTE 10 – CONVERTIBLE NOTES PAYABLE – SHORT TERM Assumed convertible debt As part of the merger, the Company assumed $891,133 of outstanding convertible debt. During the fourth quarter of 2021, the Company paid off $574,133, and signed an amendment to one of the debt agreements increasing the debt by $20,000, resulting in an outstanding balance of the assumed convertible debt as of December 31, 2021 of $337,000. The assumed convertible debt is made up of the 2019 Note and the Convertible Grid note whose terms are described below. During the nine months ended September 30, 2022, the Company converted the Grid Notes totaling $250,000 into common stock, added $33,000 of accrued interest to the 2019 Note principal as per an amendment to the agreement, and paid off $30,000 of principal of the 2019 Note, resulting in a balance of $90,000 at September 30, 2022. 2019 Note On December 31, 2019, the Company entered into a Securities Purchase Agreement and issued and sold to a third party a Convertible Note in the original principal amount of $275,000 (the “Note”), and a warrant to purchase 1,176 shares of the Company’s common stock (the “Warrant”). A one-time interest charge of 8% was applied on December 31, 2019 and will be payable, along with the Principal, on the maturity date. On December 30, 2021, the Company signed an allonge amending the Note extending the maturity date to April 30, 2022 and amending the outstanding balance and payment schedule to provide for two equal payments of $60,000 on March 31, 2022 and April 30, 2022. On March 31, 2022 the Company signed an allonge amending the Note, extending the maturity date to December 31, 2022 and amended the outstanding balance and payment schedule to provide for seven monthly payments of $10,000 plus interest at the rate of 14% per annum. The first monthly payment is payable on June 30, 2022. A final payment of $50,000 plus interest is due upon maturity. During the nine months ended September 30, 2022, the Company added accrued interest of $33,000 to the 2019 Note principal as per an amendment to the agreement, and paid off $30,000 of principal of the 2019 Note, resulting in a balance of $90,000 at September 30, 2022. The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the investor. The conversion price was set at the merger to $23.8 which is equal to 80% multiplied by the price per share used in the merger calculations. The Note contains a price-based anti-dilution provision, pursuant to which the conversion price of the Note shall be reduced upon the occurrence of certain dilutive issuances of Company securities as set forth in the Note. The conversion of the Note is also subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. In the event the Company, prior to the maturity date of the Note, issues any Security (as defined in the Note) with any term more favorable to the holder of such Security or with a term in favor of the holder of such Security that was not similarly provided to the Investor, then at the Investor’s option such term shall become a part of the Note. The Company also agreed to provide piggy-back registration rights to the investor pursuant to which the Company shall include all shares issuable upon conversion of the Note on the next registration statement the Company files with the Securities and Exchange Commission. The Note contains events of default which, among other things, entitle the Investor to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Note. Upon the occurrence of any event of default, the outstanding balance shall immediately and automatically increase to 130% of the outstanding balance immediately prior to the event of default, and the conversion price of the Note shall be redefined to equal 65% of the lowest trade accruing during the 10 consecutive Trading Days (as defined in the Note) immediately preceding the applicable Conversion Date (as defined in the Note). Nickolay Kukekov, a director of the Company, and a third party, each has personally guaranteed the repayment of the Note. The Warrant has an exercise price of $106.25 per share (the “Exercise Price”), subject to adjustments as provided in the Warrant, and has a term of five years. The Warrant contains a price-based anti-dilution provision, pursuant to which the exercise price of the Warrant shall be reduced upon the occurrence of certain dilutive issuances of securities as set forth in the Warrant, with a corresponding increase in the number of shares underlying the Warrant if the dilutive event occurs during the first three years of the Warrant, and a cashless exercise provision. The exercise of the Warrant is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. Convertible Grid Notes On April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Caleca Note”) to Thomas J. Caleca (“Caleca”), an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 8,824 shares of the Company’s common stock at a per share exercise price of $68.0 (subject to adjustment as set forth in the Caleca Warrant). Also on April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Brown Note”, and together with the Caleca Note, the “Grid Notes”) to Andrew Brown (“Brown”, and together with Caleca, the “Grid Investors”), an existing stockholder of the Company, pursuant to which Brown agreed to advance to the Company the aggregate principal amount of $125,000 (the “Brown Aggregate Advance”, and together with the Caleca Aggregate Advance, the “Aggregate Advance”). The Company also issued to Brown a common stock purchase warrant (the “Brown Warrant”, and together with the Caleca Warrant, the “Grid Warrants”), granting Brown the right to purchase up to 8,824 shares of the Company’s common stock at a per share exercise price of $68.0 (subject to adjustment as set forth in the Brown Warrant). The Grid Warrants are exercisable at any time commencing on the eighteen-month anniversary of the issuance of the Grid Warrants (as may be accelerated pursuant to the terms of the Grid Warrants) and expiring on the five-year anniversary of the issuance of the Grid Warrants. In 2021, the terms of the Grid Warrants were amended extending the first date of exercise to October 21, 2022. The Grid Notes bear interest on the unpaid balances at a fixed simple rate of twelve percent (12%) per annum (subject to a rate increase if the Company commits an Event of Default (as defined in the Grid Notes)), computed based on a 360-day year of twelve 30-day months, commencing on the date of the respective advance and payable quarterly. The principal amount of the Aggregate Advance, or so much thereof as has been advanced to the Company by the Grid Investors from time to time pursuant to the Grid Notes, was payable on April 21, 2021, which was amended to April 21, 2022. The Company had a total outstanding principal balance of $250,000 as of December 31, 2021 and accrued interest and $28,032 as of December 31, 2021, respectively. On April 20, 2022, the Grid Notes and accrued interest were converted into 3,380 shares of common stock. 2022 Notes On June 13, 2022, the Company consummated the first closing of a private placement offering whereby the Company entered into a Securities Purchase Agreement (SPA), dated as of June 13, 2022 with thirteen accredited investors, pursuant to which the investors purchased from the Company, for an aggregate purchase price of $5,110,000, (i) 10% Original Issue Discount Senior Secured Convertible Debentures (the “2022 Notes”), in the principal amount of $5,659,500 and (ii) 222,311 warrants to purchase shares of common stock of the Company at the same price as the debt conversion price. In addition, 23,713 warrants were issued to the book-runner of this offering (together with the 222,311 investor warrants – the “2022 warrants”). The 2022 Notes mature on June 13, 2023 and bear interest at an annual rate of 10%. Due the issuance costs and the derivatives associated with the 2022 Notes (see below), the Company recorded a debt discount of 4,470,289, which will be amortized using the effective interest method over the life of the loan. During the three and nine month periods ended September 30, 2022, the Company recorded discount amortization in the form of interest expense in the amounts of $553,200 and $633,312, respectively. The balance of the discount at September 30, 2022 was $3,836,977. The 2022 Warrants shall be exercisable at any time on or after the earlier of (i) the maturity date; or (ii) the closing of a registered offering of the Company’s securities for aggregate gross proceeds to the Company of at least $5,000,000, resulting in the listing for trading of the Common Stock on the NYSE American or The Nasdaq Capital Market (the “Qualified Offering”), and on or prior to December 13, 2028 (if no Qualified Offering has been consummated occurred on or prior to the maturity date of the 2022 Notes) or the date that is five years and nine months following the closing of the Qualified Offering. The 2022 Notes contain mandatory and voluntary conversion features as follows: (a) Mandatory Conversion. In the event a Qualified Offering is consummated prior to the maturity date of the 2022 Notes, the 2022 Notes automatically convert into shares of Common Stock, immediately upon the occurrence of a Qualified Offering (the “Mandatory Conversion”). The exercise price per share of Common Stock pursuant to the Warrant shall mean, in the case of a Mandatory Conversion, the price of the Common Stock (or unit, if units are offered in the Qualified Offering) in the Qualified Offering. (b) Voluntary Conversion. The holders of the 2022 Notes have the right (subject to the conversion limitations set forth therein) from time following the maturity date and prior to a Mandatory Conversion to convert all or any part of the outstanding and unpaid principal and interest then due under the 2022 Notes into fully paid and non-assessable shares of Common Stock (the “Voluntary Conversion”). The exercise price per share of Common Stock pursuant to the Warrant shall mean, in the case of a Voluntary Conversion, the lower of (i) $21.25 per share or (ii) 75% of the average of the VWAP of the Company’s Common Stock during the ten (10) Trading Day period immediately prior to the maturity date. In connection with the Offering, each of Piezo, and Memory MD, Inc., (the “Company Subsidiaries”) agreed to execute, in favor of the holders of the 2022 Notes, a guarantee to jointly and severally, unconditionally and irrevocably, guarantee to the holders the prompt and complete payment and performance when due of the Company’s obligations pursuant to the SPA. In connection with the Offering, the Company entered into a security agreement by and among the Company, each of the holders and the Company Subsidiaries, whereby the Company agreed to grant each of the holders a security interest in all of the assets of the Company, to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the 2022 Notes and the Company Subsidiaries’ obligations under the Guarantee. Long Term 2021 Notes In conjunction with the closing of the Merger on October 1, 2021, the Company conducted an initial closing under a private offering (the “Offering”) of 10% convertible promissory notes due and payable on April 1, 2023 (the “2021 Notes”). As part of the Offering, the Company exchanged the 2020 Notes and accrued interest as well as additional notes issued in 2021 with the same terms as the 2020 Notes and their accrued interest amounting to $4,328,407, as well as $1,540,508 of debt assumed in the merger into 2021 Notes. At the merger, the Company also issued a convertible promissory note to an investor in the amount of $2,950,000 with proceeds of $2,850,000 net of an original issuance discount, with the same terms as the 2021 Notes. The balance of the debt discount at December 31, 2021 was $83,364. Each holder of the 2021 Notes, provided that the note is still then outstanding, will be issued, on the earlier of (i) the date, if any, upon which the Company’s common stock is listed for trading on the NASDAQ stock exchange (the “Uplist”), and (ii) the date that is eighteen months from the date of issuance, a warrant to purchase an amount of shares of the Company’s common stock, equal to such holder’s Warrant Share Amount. For purposes of the foregoing, a holder’s “Warrant Share Amount” means (i) if such Warrant is issued in connection with the Uplist, one half of the initial principal balance of such Holder’s Note at issuance divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the closing price for the Company’s common stock on the trading day prior to the date of the Uplist, and (ii) if such Warrant is issued otherwise than in connection with the Uplist, the initial principal balance of such Holder’s Note, divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the volume weighted average price (“VWAP”) for the Company’s common stock over the five consecutive trading days immediately preceding the date that is eighteen months from the date of issuance. The 2021 Notes contain mandatory and voluntary conversion features as detailed in the agreement. On December 21, 2021, the Company consummated the second closing of the Offering whereby the Company entered into a Securities Purchase Agreement (the “SPA”) with three accredited investors, pursuant to which the investors purchased from the Company, 2021 Notes in the principal amount of $900,000. During the nine months ended September 30, 2022, the Company consummated additional closings of the Offering whereby the Company entered into a Securities Purchase Agreement (the “SPA”) with additional investors, pursuant to which the investors purchased from the Company, 2021 Notes in the principal amount of $2,000,000. As of December 31, 2021, the total amount of 2021 Notes principal outstanding was $9,718,915. As part of the issuance of the 2022 Notes, all of the 2021 Notes and accrued interest, as well as an additional 10% discount, was converted into shares of common stock. The holders of the 2021 Notes, in connection with their original investment, will also be entitled to warrants based on 50% coverage of their original investment amount. These warrants will have a term of four years after issuance and an exercise price of $21.25 per share.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2022
Derivative Financial Instruments [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS The Company evaluated the terms and conditions of the 2022 Notes (see note 10 above) under the guidance of ASC 815. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period. The Company evaluated the fair value of the derivatives utilizing the “with and without scenario” using options pricing models and Monte Carlo simulation, and a probability weighted value. As of September 30, 2022, the fair value of derivative liabilities in respect of the conversion feature and the warrants were $1,159,000 and $698,351, respectively. The following are the data and assumptions used in the conversion feature derivative valuations at the respective dates: Inception September 30, Common stock price $ 25.5 $ 10.2 Exercise price $ 28.05-30.6 28.05-30.6 Expected volatility 100.0 % 92.0-100.0 % Risk free rate 2.3-3.0 % 3.3-4.0 % Expected dividend yield 0 % 0 % Expected term (years) 0.55-1.25 0.25-0.95 Discount rate 37.7 % 37.7 % PV factor 0.67-0.84 0.80 The following are the data and assumptions used in the warrant derivative valuations at the respective dates: Inception September 30, Common stock price $ 25.5 $ 10.2 Expected volatility 100.0 % 98.0 % Expected term (years) 6.05 5.5 Risk free rate 3.5 % 4.0 % Expected dividend yield 0 % 0 % The following tables summarize the components of the Company’s derivative liabilities as of September 30, 2022 and December 31, 2021: Conversion Feature Warrants Total Balance at December 31, 2021 - - - Issuance – June 13, 2022 $ 1,610,000 $ 1,622,399 $ 3,232,399 Movement in fair value (451,000 ) (924,048 ) (1,375,048 ) Balance at September 30, 2022 $ 1,159,000 $ 698,351 $ 1,857,351

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 12 – NOTES PAYABLE December 28, 2020 Note On December 28, 2020, the Company entered into a Securities Purchase Agreement (the “December Purchase Agreement”) dated as of December 28, 2020 (the “December 28 Issuance Date”) and issued and sold to an investor a Promissory Note (the “December 28 Note”) in the aggregate principal amount of $300,000. Pursuant to the December Purchase Agreement, in connection with the issuance of the December 28 Note, the Company issued two common stock purchase warrants (separately, “Warrant A” and “Warrant B”, and together, the “December Warrants”) to the investor, allowing the investor to purchase an aggregate of 5,882 shares of the Company’s common stock, with Warrant A being a commitment fee of 2,941 shares of common stock, and Warrant B being fully earned upon issuance as an additional commitment fee of 2,941 shares of common stock, provide that Warrant B is returnable to the Company upon the repayment of the December 28 Note, as an additional incentive for the repayment of the December 28 Note. The net amount received by the Company during the year ended December 31, 2020 was approximately $265,000 after payment of certain fees to the investor or on behalf of the investor. The December 28 Note bears interest commencing on the December 28 Issuance Date at a fixed rate of 12% per annum on any unpaid principal balance, and will be payable, along with the principal amount, on December 28, 2021. A lump-sum interest payment for one year is due on the December 28 Issuance Date and added to the principal balance and payable on the maturity date of the December 28 Note or upon acceleration or by prepayment or otherwise, notwithstanding the number of days which the principal is outstanding. Principal payments shall be made in 6 installments each in the amount of $56,000 commencing 180 days following the Issue Date (as defined in the Note) and continuing thereafter each 30 days for 5 months. The Company recorded debt discount of $300,000 related to the December 28 Note, which was fully amortized as of December 31, 2021. On December 28, 2021, the December 28 Note was amended to add $33,600 of interest, and to amend the payment terms to two equal payments of $184,800 due on February 28, 2022 and March 31, 2022. During the nine months ended September 30, 2022, the Company repaid all of the outstanding principal and interest. The December Warrants each have an exercise price of $102.0, subject to customary adjustments, and may be exercised at any time until the three-year anniversary of the December Warrants. The December Warrants include a cashless exercise provision as set forth therein.

Notes Payable _ Related Party

Notes Payable – Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Notes Payable – Related Party [Abstract]
NOTES PAYABLE – RELATED PARTY	NOTE 13 – NOTES PAYABLE – RELATED PARTY As part of the October 1, 2021 merger with Piezo. and BRSF Acquisition Corp., the Company assumed $155,530 of related party loans from entities related to the former executives and directors of the Company. When assumed, these loans did not bear interest and had a maturity date of December 31, 2021. On March 9, 2022, the loans were amended to provide for an interest rate of 9% per annum, and to extend the maturity dates to provide for payments of $53,000 with accrued interest on March 31, 2022 and June 1, 2022, and a payment of $49,000 plus accrued interest on August 1, 2022. On May 6, 2022 the payment terms were further amended to payments of $53,000 with accrued interest on May 31, 2022 and August 1, 2022, and a payment of $49,000 plus accrued interest on October 1, 2022. The Company has an outstanding loan from an officer of the Russian subsidiary in the amount of RUB 34,400. Interest and payment terms have not been determined. The USD equivalent at September 30, 2022 was $596.	NOTE 12 – LOANS PAYABLE - RELATED PARTY As part of the merger, the Company assumed $155,989 of related party loans from entities related to the former executives and directors the Company. These loans do not bear interest and had an initial maturity date of December 31, 2021. On March 9, 2022, the loans were amended to adjust the interest rate to 9% per annum, and to extend the maturity dates to provide for payments of $53,000 with accrued interest on March 31, 2022 and June 1, 2022, and a payment of $49,000 plus accrued interest on August 1, 2022.

Leases

Leases	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
LEASES	NOTE 14 – LEASES The Company has two leases that are accounted for under ASC 842. The Company entered into a lease agreement for office space located in Sarasota, Florida. The term of the lease is for a period of two years commencing on February 1, 2021 and ending on February 1, 2023. The rent is $6,530 per month for year 1, $6,726 per month for year 2 and $6,928 per month for year 3. The Company will account for the lease under ASC 842 whereby the operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company had a lease agreement with terms up to 2 years for the lease of office space. The assets and liabilities from operating leases were recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. This lease was settled on January 1, 2022, and the Company recorded a gain of $1,660 in respect of the early settlement. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating lease does not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate used at the date closest to lease inception. The Company’s weighted-average remaining lease term relating to its operating leases is 1.9 years, with a weighted-average discount rate of 10.32%. The Company incurred lease expense for its operating leases of $64,490 and $0 which was included in “General and administrative expenses,” for the nine months ended September 30, 2022 and 2021, respectively. The following table presents information about the amount and timing of liabilities arising from the Company’s operating lease as of September 30, 2022: Maturity of operating lease liabilities for the following fiscal years: 2022 $ 21,491 2023 88,325 2024 7,378 Total undiscounted finance lease payments 117,194 Less: Imputed interest (7,032 ) Present value of finance lease liabilities $ 110,162   At September 30, 2022, the operating lease right of use assets was $107,617. Supplemental balance sheet information related to the lease as of September 30, 2022 was: Operating lease right-of-use asset $ 107,617 Lease liability, current portion 81,012 Lease liability, long-term 29,150 Total operating lease liability $ 110,162	NOTE 13 – LEASES   The Company has two leases that are accounted for under ASC 842. The Company entered into a lease agreement for office space located in Sarasota, Florida. The term of the lease is for a period of two years commencing on February 1, 2021 and ending on February 1, 2023. The rent is $6,530 per month for year 1, $6,726 per month for year 2 and $6,928 per month for year 3. The Company will account for the lease under ASC 842 whereby the operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company has a lease agreement with terms up to 2 years for the lease of office space. The assets and liabilities from operating leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating lease does not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate used at the date closest to lease inception. The Company’s weighted-average remaining lease term relating to its operating leases is 1.9 years, with a weighted-average discount rate of 10.32%. The Company incurred lease expense for its operating leases of $83,469 and $0 which was included in “General and administrative expenses,” for the year ended December 31, 2021 and 2020, respectively. The following table presents information about the amount and timing of liabilities arising from the Company’s operating lease as of December 31, 2021: Maturity of operating lease liabilities for the following fiscal years: 2022 $  118,452 2023 88,325 2024 7,379 Total undiscounted finance lease payments 214,156 Less: Imputed interest 18,475 Present value of finance lease liabilities $  195,681   At December 31, 2021, the operating lease right of use assets was $69,632. Supplemental balance sheet information related to the lease as of December 31, 2021 was: Operating lease right-of-use asset $ 191,702 Lease liability, current portion 104,592 Lease liability, long-term 91,089 Total operating lease liability $ 195,681

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stockholders' Deficit [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 15 – STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 10,000,000 shares of undesignated preferred stock with a $0.001 par value. As of September 30, 2022, no preferred shares have been issued and these shares are considered blank check preferred shares with no terms, limitations, or rights associated with them. Common Stock The Company has authorized 750,000,000 shares of common stock with a $0.001 par value per share. The holders of common stock are entitled to one vote for each share of common stock held at the time of vote. As of September 30, 2022, the Company had 1,240,094 shares outstanding or deemed outstanding. Shares Issued for Services In January 2022, the Company issued 4,243 shares to a service provider in respect of $129,850 of outstanding payables. Warrants The following table summarized the warrant activity for the nine months ended September 30, 2022: Number of Weighted Weighted Aggregate Warrants Shares Price Term Value Balance Outstanding, December 31, 2021 108,922 $ 38.25 6.85 $ 304,799 Granted 246,024 7.65 5.20 - Forfeited (554 ) - - - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2022 354,392 $ 17.0 5.45 - Exercisable, September 30, 2022 90,719 $ 32.3 6.83 - Equity Incentive Plan As of September 21, 2018, the Company’s board of directors adopted, and stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan has a 10-year term, which terminates on the day prior to the 10 th On October 1, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 52,990 shares of common stock to an executive and a director. The options have an exercise price of $29.75 per share and vested immediately upon issuance. The options will expire on October 1, 2031. The aggregate fair value of $1,270,188 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115%, (iii) risk free rate of 0.93% (iv) dividend rate of zero, (v) stock price of $29.75, and (vi) exercise price of $29.75. The expense of 1,270,188 was recorded in full upon issuance. On October 21, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 14,332 shares of common stock to the CEO. The options have an exercise price of $33.15 per share with vesting terms of 3,583 vesting on April 21, 2022 and the remainder monthly ratably through October 21, 2023. The options will expire on October 21, 2031. The aggregate fair value of $372,384 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 4.65 years, (ii) volatility of 113.90%, (iii) risk free rate of 1.22% (iv) dividend rate of zero, (v) stock price of $33.15, and (vi) exercise price of $33.15. These options were amended on December 10, 2021 and December 30, 2021 adjusting the exercise price to $17.85 and the vesting schedule to vest equally at the end of each quarter in 2022. The expense will be amortized over the amended vesting period and a total of $36,667 was recorded during the year ended December 31, 2021. On December 10, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 31,979 shares of common stock to the certain employees of the Company. The options have an exercise price of $17.85 per share with vesting terms of one quarter vesting on June 10, 2022 and the remainder monthly ratably through December 10, 2023. The options will expire on December 11, 2031. The aggregate fair value of $472,975 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 116.90%, (iii) risk free rate of 1.26% (iv) dividend rate of zero, (v) stock price of $17.85, and (vi) exercise price of $17.85. These options were amended on December 30, 2021 adjusting the vesting schedule to vest equally at the end of each quarter in 2022. As the share price had increased on the amendment date, the amendment resulted in an increase to the aggregate fair value of $111,166. The increased fair value along with the unamortized portion of the original fair value will be amortized over the amended vesting schedule. A total of $26,574 was recorded during the year ended December 31, 2021. On November 15, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 17,039 shares of common stock to the directors of the Company. The options have an exercise price of $24.65 per share and vest per days in service as members of the board of directors during the quarter, at the end of the quarter with the final quarterly vesting quarter end of December 31, 2022. The options will expire on December 11, 2031. The aggregate fair value of $341,793 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5.04 years, (ii) volatility of 115.8%, (iii) risk free rate of 1.25% (iv) dividend rate of zero, (v) stock price of $24.65, and (vi) exercise price of $24.65. The expense will be amortized over the vesting period and a total of $28,254 was recorded during the year ended December 31, 2021. On May 19, 2022, the Board of Directors approved the issuance of options to purchase an aggregate of 12,778 shares of common stock to certain employees of the Company. The options have an exercise price of $26.35 per share with vesting terms of one quarter/half vesting on November 19, 2022 and the remainder monthly ratably through May 19, 2023. The options will expire on May 19, 2032. The aggregate fair value of $271,324 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115.0%, (iii) risk free rate of 2.80% (iv) dividend rate of zero, (v) stock price of $26.35, and (vi) exercise price of $26.35. The expense will be amortized over the vesting period and a total of $99,491 was recorded since issuance and through September 30, 2022. On August 19, 2022, the Board of Directors approved the issuance of options to purchase an aggregate of 303,390 shares of common stock to certain employees of the Company. The options have an exercise price of $10.2 per share with varying vesting terms through August 10, 2023. The options will expire on August 19, 2027. The aggregate fair value of $2,346,000 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 100.0%, (iii) risk free rate of 3.10% (iv) dividend rate of zero, (v) stock price of $10.2, and (vi) exercise price of $10.2. The expense will be amortized over the vesting period and a total of $2,277,618 was recorded since issuance and through September 30, 2022. The following table summarized the option activity for the nine months ended September 30, 2022: Number of Weighted Weighted Aggregate Options Shares Price Term Value Balance Outstanding, December 31, 2021 138,275 $ 30.6 9.47 $ 196,825 Granted 316,168 11.05 5.00 - Forfeited (5,602 ) 17.85 9.20 - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2022 448,841 $ 17.0 6.15 - Exercisable, September 30, 2022 415,819 $ 17.0 5.98 - For future periods, the remaining value of the stock options totaling approximately $513,807 will be amortized into the statement of operations consistent with the period for which the services will be rendered.	NOTE 14 – STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 10,000,000 shares of undesignated preferred stock with a $0.001 par value. As of December 31, 2021, no preferred shares have been issued and these shares are considered blank check preferred shares with no terms, limitations, or rights associated with them. Common Stock The Company has authorized 200,000,000 shares of common stock with a $0.001 par value per share. The holders of common stock are entitled to one vote for each share of common stock held at the time of vote. As of December 31, 2021, the Company has deemed 590,857 shares outstanding or deemed outstanding. Shares Issued for Services On October 15, 2020, the Company granted to a non-executive officer of the Company 3,437 restricted shares under the Company’s 2018 Equity Incentive Plan. The shares were valued as of the date of the grant at a fair value of $1.67 per share or $487,931, which will be amortized over the vesting period. As a result of the merger and contractual terms of the restricted share agreement, all the remaining unvested shares vested and the Company recorded $280,369 in stock-based compensation. The Company issued 128 shares of common stock and withheld 2,168 shares in respect of tax withholdings. The following table summarized the warrant activity for the years ended December 31, 2021 and 2020: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2019 5,908 $ 48.45 3.98 $ 201,125 Granted 41,540 86.7 3.90 150,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 47,448 $ 82.45 3.39 $ 351,125 Granted 70,332 16.15 9.52 304,799 Forfeited - - - - Exercised - - - - Expired (8,858 ) 102.0 1.73 - Balance Outstanding, December 31, 2021 108,922 $ 38.25 6.85 $ 304,799 Exercisable, December 31, 2021 108,922 $ 27.2 6.85 $ 304,799 Equity Incentive Plan As of September 21, 2018, the Company’s board of directors adopted, and stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan has a 10-year term, which terminates on the day prior to the 10 th On January 30, 2020, the Board of Directors approved the issuance of options to purchase an aggregate of 9,412 shares of common stock to Boris Goldstein. The options have an exercise price of $63.75 per share which will vest ratably on a quarterly basis over a two-year period. The options will expire on January 30, 2029. The aggregate fair value of $51,757 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 76%, (iii) risk free rate of 1.57% (iv) dividend rate of zero, (v) stock price of $10.2, and (vi) exercise price of $63.75. The expense will be amortized over the vesting period and a total of $23,790 was recorded during the year ended December 31, 2020. On October 1, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 52,990 shares of common stock to an executive and a director. The options have an exercise price of $29.75 per share and vested immediately upon issuance. The options will expire on October 1, 2031. The aggregate fair value of $1,270,188 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115%, (iii) risk free rate of 0.93% (iv) dividend rate of zero, (v) stock price of $29.75, and (vi) exercise price of $29.75. The expense of 1,270,188 was recorded in full upon issuance. On October 21, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 14,332 shares of common stock to the CEO. The options have an exercise price of $33.15 per share with vesting terms of 3,583 vesting on April 21, 2022 and the remainder monthly ratably through October 21, 2023. The options will expire on October 21, 2031. The aggregate fair value of $372,384 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 4.65 years, (ii) volatility of 113.90%, (iii) risk free rate of 1.22% (iv) dividend rate of zero, (v) stock price of $33.15, and (vi) exercise price of $33.15. These options were amended on December 10, 2021 and December 30, 2021 adjusting the exercise price to $17.85 and the vesting schedule to vest equally at the end of each quarter in 2022. The expense will be amortized over the amended vesting period and a total of $36,667 was recorded during the year ended December 31, 2021. On December 10, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 31,979 shares of common stock to the certain employees of the Company. The options have an exercise price of $17.85 per share with vesting terms of one quarter vesting on June 10, 2022 and the remainder monthly ratably through December 10, 2023. The options will expire on December 11, 2031. The aggregate fair value of $472,975 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 116.90%, (iii) risk free rate of 1.26% (iv) dividend rate of zero, (v) stock price of $17.85, and (vi) exercise price of $17.85. These options were amended on December 30, 2021 adjusting the vesting schedule to vest equally at the end of each quarter in 2022. As the share price had increased on the amendment date, the amendment resulted in an increase to the aggregate fair value of $111,166. The increased fair value along with the unamortized portion of the original fair value will be amortized over the amended vesting schedule. A total of $26,574 was recorded during the year ended December 31, 2021. On November 15, 2021, the Board of Directors approved the issuance of options to purchase an aggregate of 17,039 shares of common stock to the directors of the Company. The options have an exercise price of $24.65 per share and vest per days in service as members of the board of directors during the quarter, at the end of the quarter with the final quarterly vesting quarter end of December 31, 2022. The options will expire on December 11, 2031. The aggregate fair value of $341,793 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5.04 years, (ii) volatility of 115.8%, (iii) risk free rate of 1.25% (iv) dividend rate of zero, (v) stock price of $24.65, and (vi) exercise price of $24.65. The expense will be amortized over the vesting period and a total of $28,254 was recorded during the year ended December 31, 2021. The following table summarized the option activity for the years ended December 31, 2021 and 2020: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2019 11,765 $ 63.75 9.05 $ 150,000 Granted 9,412 $ 63.75 10.00 120,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 21,177 $ 63.75 8.51 $ 270,000 Granted 118,007 25.50 9.82 196,825 Forfeited (909 ) 127.50 9.12 Exercised Expired Balance Outstanding, December 31, 2021 138,275 $ 30.6 9.47 $ 196,825 Exercisable, December 31, 2021 76,908 $ 18.7 9.14 $ - For future periods, the remaining value of the stock options totaling approximately $1,266,050 will be amortized into the statement of operations consistent with the period for which the services will be rendered.

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 16 – RELATED PARTY TRANSACTIONS The Company rents office space from a company in which Hassan Kotob, CEO, has an ownership. For the three and nine months ended September 30, 2022 and 2021, the Company incurred rental expense of $9,900 and $29,700, respectively, in respect of this office. On November 12, 2021, the Company entered into a Representation Agreement with LOK Corporation International Inc. (“LOK”), a corporation in which Daniel Cloutier, a director, serves as the chief executive officer. Under the Representation Agreement, LOK acts as the worldwide sales manager for our NeuroCap, NeuroEEG and their accessories. LOK is responsible for the evaluation of regional distribution, development, recruitment and training of the distribution network and provide in-country customer support. Fees for the services are 10% of sales occurring through the distribution channels. The contract term is for three years. To date, we have paid LOK approximately $4,750 for training platform development but no other service fees and no commissions.	NOTE 15 – RELATED PARTY TRANSACTIONS The Company rents office space from a company in which Hassan Kotob, CEO, has an ownership. For the year ended December 31, 2021, the Company incurred rental expense of $39,600 in respect of this office. In addition, the Company during 2021 the Company expensed an amount of $29,700 of rental expense on behalf of 2020. As a result, the total amount of rent expense paid to a related party was $69,300 in 2021. As of December 31, 2021, the Company had loans payable from related parties amounting to $155,989. The loans bear no interest and are due on December 31, 2021. These loans were amended after the balance sheet date (see Note 19). On November 12, 2021, the Company entered into a Representation Agreement with LOK Corporation International Inc. (“LOK”), a corporation in which Daniel Cloutier, a director, serves as the chief executive officer. Under the Representation Agreement, LOK acts as the worldwide sales manager for our NeuroCap, NeuroEEG and their accessories. LOK is responsible for the evaluation of regional distribution, development, recruitment and training of the distribution network and provide in-country customer support. Fees for the services are 10% of sales occurring through the distribution channels. The contract term is for three years. To date, we have paid LOK approximately $4,750 for training platform development but no other service fees and no commissions.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 17 – COMMITMENTS AND CONTINGENCIES On February 18, 2022, the Company signed an outsourced manufacturing agreement with Bioana, S.A.P.I. DE C.V. The agreement is for three years, ending December 31, 2024 for a minimum order quantity of 10,000 NeuroCaps per annum. Unit cost for the NeuroCap is fixed for the first year ending December 31, 2022. The approximate cost for this agreement in 2022 is $350,000. The manufacturing agreement will renew annually unless terminated in writing by one of the parties.	NOTE 18 – COMMITMENTS AND CONTINGENCIES On February 18, 2022, the Company signed an outsourced manufacturing agreement with Bioana, S.A.P.I. DE C.V. The agreement is for three years, ending December 31, 2024 for a minimum order quantity of 10,000 NeuroCaps per annum. Unit cost for the NeuroCap is fixed for the first year ending December 31, 2022. The manufacturing agreement will renew annually unless terminated in writing by one of the parties.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 18 – SUBSEQUENT EVENTS In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued, and the following subsequent events took place. In the fourth quarter of 2022, the Company repaid approximately $34,000 of principal and interest of the Notes payable – Related party, bringing the balance at December 31, 2022 to $14,514. The Company is currently negotiating the settlement of the remaining balance. On January 1, 2023, the Company amended the 2019 Note extending the maturity date to February 15, 2023, at which time the Company will make one payment of $60,700 plus an extension fee of $2,500, for a total of $63,200.	NOTE 19 – SUBSEQUENT EVENTS In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued and the following subsequent events took place. On February 18, 2022, the Company signed an outsourced manufacturing agreement with Bioana, S.A.P.I. DE C.V. The agreement is for three years, ending December 31, 2024 for a minimum order quantity of 10,000 NeuroCaps per annum. Unit cost for the NeuroCap is fixed for the first year ending December 31, 2022. The manufacturing agreement will renew annually unless terminated in writing by one of the parties. The Company received $2,000,000 of new monies through our private placement offering for convertible debt in 2022. As part of the issuance of the 2022 Notes, all of the 2021 Notes and accrued interest, as well as an additional 10% discount, was converted into shares of common stock. The holders of the 2021 Notes, in connection with their original investment, will also be entitled to warrants based on 50% coverage of their original investment amount. These warrants will have a term of four years after issuance and an exercise price of $21.25 per share. On March 31, 2022 the Company signed an allonge amending its December 31, 2019 convertible promissory note in the original principal amount of $275,000 (the “Note”). The allonge extended the maturity date to December 31, 2022 and amended the outstanding balance and payment schedule to provide for seven monthly payments of $10,000 plus interest at the rate of 14% per annum with a final payment of $50,000 plus interest due upon maturity. The Company repaid $60,000 during the year ended 2022. On January 1, 2023, the Company further amended the Note extending the maturity date to February 15, 2023, at which time the Company will make one payment of $60,700 plus an extension fee of $2,500, for a total of $63,200. On April 20, 2022, the Grid Notes and accrued interest were converted into 3,380 shares of common stock. On June 13, 2022, the Company consummated the first closing of a private placement offering whereby the Company entered into a Securities Purchase Agreement (SPA), dated as of June 13, 2022 with thirteen accredited investors, pursuant to which the investors purchased from the Company, for an aggregate purchase price of $5,110,000, (i) 10% Original Issue Discount Senior Secured Convertible Debentures (the “2022 Notes”), in the principal amount of $5,659,500 and (ii) 222,311 warrants to purchase shares of common stock of the Company at the same price as the debt conversion price. In addition, 23,713 warrants were issued to the book-runner of this offering (together with the 222,311 investor warrants – the “2022 warrants”). The 2022 Notes mature on June 13, 2023 and bear interest at an annual rate of 10%. Due the issuance costs and the derivatives associated with the 2022 Notes, the Company recorded a debt discount of 4,470,289, which will be amortized using the effective interest method over the life of the loan. During year ended December 31, 2022, the Company repaid all of the December 28 Note outstanding principal and interest. On May 26, 2022 the related party loans payment terms were further amended to payments of $53,000 with accrued interest on June 30, 2022 and September 1, 2022, and a payment of $49,000 plus accrued interest on November 1, 2022. During the year ended December 31, 2022, the Company repaid $140,000 of the outstanding principal. On January 31, 2023 the Company filed an Amendment to the Certificate of Incorporation to effectuate a reverse split of the Company’s issued and outstanding common stock at an exchange ratio of 1-for -85. The reverse stock split was effective as of February 3, 2023. All share and per share data in the accompanying consolidated financial statements and footnotes has been retroactively restated to reflect the effects of the reverse stock split.

Notes Payable_2

Notes Payable	12 Months Ended
	Dec. 31, 2021
Notes Payable [Abstract] [Standard Label]
NOTES PAYABLE	NOTE 10 – NOTES PAYABLE As part of the merger, the Company assumed the following two notes payable: February 21, 2020 Note On February 21, 2020, a third party loaned the Company $20,000, evidenced by a non-convertible promissory note (the “February Note”). The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal outstanding and any accrued and unpaid interest due under the February Note were due on February 22, 2022. The Company recorded $3,593 of accrued interest and has a total outstanding principal balance of $20,000 as of December 31, 2021. The February note and accrued interest was repaid on February 22, 2022. December 28, 2020 Note On December 28, 2020, the Company entered into a Securities Purchase Agreement (the “December Purchase Agreement”) dated as of December 28, 2020 (the “December 28 Issuance Date”) and issued and sold to an investor a Promissory Note (the “December 28 Note”) in the aggregate principal amount of $300,000. Pursuant to the December Purchase Agreement, in connection with the issuance of the December 28 Note, the Company issued two common stock purchase warrants (separately, “Warrant A” and “Warrant B”, and together, the “December Warrants”) to the investor, allowing the investor to purchase an aggregate of 5,882 shares of the Company’s common stock, with Warrant A being a commitment fee of 2,941 shares of common stock, and Warrant B being fully earned upon issuance as an additional commitment fee of 2,941 shares of common stock, provided that Warrant B is returnable to the Company upon the repayment of the December 28 Note, as an additional incentive for the repayment of the December 28 Note. The net amount received by the Company during the year ended December 31, 2020 was approximately $265,000 after payment of certain fees to the investor or on behalf of the investor. The December 28 Note bears interest commencing on the December 28 Issuance Date at a fixed rate of 12% per annum on any unpaid principal balance, and will be payable, along with the principal amount, on December 28, 2021. At issuance, the Company recorded debt discount of $300,000 related to the December 28 Note. Amortization of the debt discount is recorded as interest expense and a total of $73,151 was amortized during the year ended December 31, 2021. The initial maturity date for the December 28 Note was December 28, 2021. On December 28, 2021, the Company signed an allonge with the investor amending the note. The terms of the amended note provided for two equal payments of $184,800, due on February 28, 2022 and March 31, 2022. The December 28 Note contains customary events of default which entitle the investor, among other things, to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the December 28 Note. Upon an event of default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. The December 28 Note further contains monetary penalties in the event of certain events of default or breaches. The December Warrants each have an exercise price of $102.0, subject to customary adjustments, and may be exercised at any time until the three-year anniversary of the December Warrants; provided, however, in the event the Company repays the December 28 Note in its entirety on or prior to the maturity date of the December 28 Note, Warrant B shall automatically expire and may only be exercised in the event it does not so automatically expire. The December Warrants include a cashless exercise provision as set forth therein. Notes payable as of December 31, 2020 amounted to $650,000 and are described in Note 11 below. They were converted into convertible notes payable at the merger on October 1, 2021.

Convertible Notes Payable, Net

Convertible Notes Payable, Net	12 Months Ended
	Dec. 31, 2021
Convertible Notes Payable, Net [Abstract]
CONVERTIBLE NOTES PAYABLE, NET	NOTE 11 – CONVERTIBLE NOTES PAYABLE, NET 2020 Notes In July 2020, Motion made an offering of convertible notes not to exceed approximately $2,400,000. In October and extended in April, June and August 2021, the Board authorized increasing the potential investment to not exceed $5,000,000. These notes are payable by October 13, 2021, interest accruing at 10% per annum. At the completion of a qualifying investment, the Company, at its sole discretion may convert the loans and any accrued interest to common stock with a 120% multiplier on the value of the common stock in the qualifying investment. As of September 30, 2021 and December 31, 2020, the carrying amount of these notes was $4,119,982 and $650,000, respectively with accrued interest of $208,480 and $26,766, respectively. On October 1, 2021, the outstanding balances and accrued interest were exchanged for new notes payable as part of the merger. 2021 Notes In conjunction with the closing of the Merger on October 1, 2021, the Company conducted an initial closing under a private offering (the “Offering”) of 10% convertible promissory notes due and payable on April 1, 2023 (the “2021 Notes”). As part of the Offering, the Company exchanged the 2020 Notes and accrued interest as well as additional notes issued in 2021 with the same terms as the 2020 Notes and their accrued interest amounting to $4,328,407, as well as $1,540,508 of debt assumed in the merger into 2021 Notes. At the merger, the Company also issued a convertible promissory note to an investor in the amount of $2,950,000 with proceeds of $2,850,000 net of an original issuance discount, with the same terms as the 2021 Notes. Each holder of the 2021 Notes, provided that the note is still then outstanding, will be issued, on the earlier of (i) the date, if any, upon which the Company’s common stock is listed for trading on the NASDAQ stock exchange (the “Uplist”), and (ii) the date that is eighteen months from the date of issuance, a warrant to purchase an amount of shares of the Company’s common stock, equal to such holder’s Warrant Share Amount. For purposes of the foregoing, a holder’s “Warrant Share Amount” means (i) if such Warrant is issued in connection with the Uplist, one half of the initial principal balance of such Holder’s Note at issuance divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the closing price for the Company’s common stock on the trading day prior to the date of the Uplist, and (ii) if such Warrant is issued otherwise than in connection with the Uplist, the initial principal balance of such Holder’s Note, divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the volume weighted average price (“VWAP”) for the Company’s common stock over the five consecutive trading days immediately preceding the date that is eighteen months from the date of issuance. On December 21, 2021, the Company consummated the second closing of the Offering whereby the Company entered into a Securities Purchase Agreement (the “SPA”) with three accredited investors, pursuant to which the investors purchased from the Company, 2021 Notes in the principal amount of $900,000. As of December 31, 2021, the total amount of 2021 Notes principal outstanding was $9,718,915. Assumed convertible debt As part of the merger, the Company assumed $891,133 of outstanding convertible debt. During the fourth quarter of 2021, the Company paid off $574,133, and signed an amendment increasing the debt by $20,000, resulting in an outstanding balance of the assumed convertible debt as of December 31, 2021 of $337,000. 2019 Note On December 31, 2019, the Company entered into a Securities Purchase Agreement and issued and sold to a third party a Convertible Note in the original principal amount of $275,000 (the “Note”), and a warrant to purchase 1,176 shares of the Company’s common stock (the “Warrant”). A one-time interest charge of 8% was applied on December 31, 2019 and will be payable, along with the Principal, on the maturity date. On December 30, 2021, the Company signed an allonge amending the Note extending the maturity date to April 30, 2022 and amending the outstanding balance and payment schedule to provide for two equal payments of $60,000 on March 31, 2022 and April 30, 2022. The outstanding principal balance as of December 31, 2021 was $87,000. The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the investor. The conversion price was set at the merger to $23.8 which is equal to 80% multiplied by the price per share used in the merger calculations. The Note contains a price-based anti-dilution provision, pursuant to which the conversion price of the Note shall be reduced upon the occurrence of certain dilutive issuances of Company securities as set forth in the Note. The conversion of the Note is also subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. In the event the Company, prior to the maturity date of the Note, issues any Security (as defined in the Note) with any term more favorable to the holder of such Security or with a term in favor of the holder of such Security that was not similarly provided to the Investor, then at the Investor’s option such term shall become a part of the Note. The Company also agreed to provide piggy-back registration rights to the investor pursuant to which the Company shall include all shares issuable upon conversion of the Note on the next registration statement the Company files with the Securities and Exchange Commission. The Note contains events of default which, among other things, entitle the Investor to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Note. Upon the occurrence of any event of default, the outstanding balance shall immediately and automatically increase to 130% of the outstanding balance immediately prior to the event of default, and the conversion price of the Note shall be redefined to equal 65% of the lowest trade accruing during the 10 consecutive Trading Days (as defined in the Note) immediately preceding the applicable Conversion Date (as defined in the Note). Nickolay Kukekov, a director of the Company, and a third party, each has personally guaranteed the repayment of the Note. The Warrant has an exercise price of $106.25 per share (the “Exercise Price”), subject to adjustments as provided in the Warrant, and has a term of five years. The Warrant contains a price-based anti-dilution provision, pursuant to which the exercise price of the Warrant shall be reduced upon the occurrence of certain dilutive issuances of securities as set forth in the Warrant, with a corresponding increase in the number of shares underlying the Warrant if the dilutive event occurs during the first three years of the Warrant, and a cashless exercise provision. The exercise of the Warrant is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. Convertible Grid Notes On April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Caleca Note”) to Thomas J. Caleca (“Caleca”), an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 8,824 shares of the Company’s common stock at a per share exercise price of $68.0 (subject to adjustment as set forth in the Caleca Warrant). Also on April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Brown Note”, and together with the Caleca Note, the “Grid Notes”) to Andrew Brown (“Brown”, and together with Caleca, the “Grid Investors”), an existing stockholder of the Company, pursuant to which Brown agreed to advance to the Company the aggregate principal amount of $125,000 (the “Brown Aggregate Advance”, and together with the Caleca Aggregate Advance, the “Aggregate Advance”). The Company also issued to Brown a common stock purchase warrant (the “Brown Warrant”, and together with the Caleca Warrant, the “Grid Warrants”), granting Brown the right to purchase up to 8,824 shares of the Company’s common stock at a per share exercise price of $68.0 (subject to adjustment as set forth in the Brown Warrant). The Grid Warrants are exercisable at any time commencing on the eighteen-month anniversary of the issuance of the Grid Warrants (as may be accelerated pursuant to the terms of the Grid Warrants) and expiring on the five-year anniversary of the issuance of the Grid Warrants. The Grid Notes bear interest on the unpaid balances at a fixed simple rate of twelve percent (12%) per annum (subject to a rate increase if the Company commits an Event of Default (as defined in the Grid Notes)), computed based on a 360-day year of twelve 30-day months, commencing on the date of the respective advance and payable quarterly. The principal amount of the Aggregate Advance, or so much thereof as has been advanced to the Company by the Grid Investors from time to time pursuant to the Grid Notes, will be payable on April 21, 2021, unless sooner converted into shares of the Company’s common stock pursuant to the terms of the Grid Notes. The Company recorded $28,032 of accrued interest and has a total outstanding principal balance of $250,000 as of December 31, 2021. The unpaid outstanding principal amount and accrued and unpaid interest under the Grid Notes shall be convertible at any time prior to the maturity date of the Grid Notes at the election of the Grid Investors into such number of shares of the Company’s common stock obtained by dividing the amount so converted by $1.00 (the “Conversion Price”). At the maturity date of the Grid Notes, all of the remaining unpaid outstanding principal amount and accrued and unpaid interest (the “Outstanding Balance”) under the Grid Notes shall automatically convert into such number of shares of the Company’s common stock obtained by dividing the Outstanding Balance by the Conversion Price. The Grid Notes may not be prepaid by the Company in whole or in part without the prior written consent of the respective Grid Investor. The Grid Notes contain customary events of default, which, if uncured, entitle the Grid Investors to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, their Grid Notes.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
INCOME TAXES	NOTE 16 – INCOME TAXES The Company files corporate income tax returns in the United States (federal) and New York. The Company is subject to federal, state and local income tax examinations by tax authorities through inception. As of December 31, 2021 and 2020, the Company had federal and state net operating loss carry forwards of $16,883,400 and $12,254,418, respectively that may be offset against future taxable income. Of the total amount of available losses 5,239,877 can be used to offset 100% of future income and will begin to expire in 2031 through 2037. The remaining losses have an infinite carry forward but can only reduce future taxable income a maximum of 80% annually. Due to various business combination and transactions some or all the net operating losses may be limited by operation of Internal Revenue Code Section 382. The tax effects of temporary differences which give rise to deferred tax assets (liabilities) are summarized as follows: For the Years Ended 2021 2020 Net operating loss carry forwards $ 4,181,841 $ 2,252,985 Share-based compensation 806,997 90,110 Accrued expenses 301,422 19,009 Intangible assets 100,736 107,187 Fixed assets (29,877 ) (23,039 ) Valuation allowance (5,361,119 ) (2,446,252 ) Net Deferred Tax Asset $ - $ - In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realizability. Reconciliation of the statutory federal income tax to the Company’s effective tax: For the Years Ended 2021 2020 Statutory federal tax rate 21.0 % 21.0 % State tax expense 4.7 % 4.3 % Acquired deferred tax assets 7.8 % - % PPP loan forgiveness 0.3 % - % Change in tax rate (0.9 )% - % Amortization (0.4 )% - % Other permanent items (0.3 )% (0.1 )% Valuation allowance (32.2 )% (25.2 )% Provision for income taxes - % - % The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2021 and 2020 the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2021 and 2020. The Company did not recognize any interest or penalties during fiscal 2021 or 2020 related to unrecognized tax benefits. All tax years remain open to examination for federal income tax purposes and by other major taxing jurisdictions to which the Company is subject.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
CONCENTRATIONS	NOTE 17 – CONCENTRATIONS In the years ending December 31, 2021, respectively, the Company purchased 100.0% of its medical devices for resale and distribution from Neurotech, a company that Vadim Sakharov, a former director and executive officer of the Company, is a shareholder and executive manager.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”).	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”).
Reverse Stock Split	Reverse Stock Split In connection with preparing for its share offering, the Company effected a one-for-85 reverse stock split of the Company’s common stock. The reverse stock split became effective on February 3, 2023. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share amounts in the financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The financial statements have also been retroactively adjusted to reflect adjustments to the amounts and conversion prices for convertible debt, stock options and warrants affected in connection with the reverse stock split.	Reverse Stock Split In connection with preparing for its share offering, the Company effected a one-for-85 reverse stock split of the Company’s common stock. The reverse stock split became effective on February 3, 2023. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share amounts in the financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The financial statements have also been retroactively adjusted to reflect adjustments to the amounts and conversion prices for convertible debt, stock options and warrants affected in connection with the reverse stock split.
Principles of Consolidation	Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its subsidiaries, Piezo Motion Corp, Discovery Technology International, Inc., MemoryMD US, MemoryMD – Russia and MemoryMD - Europe. All significant consolidated transactions and balances have been eliminated in consolidation.	Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its subsidiaries, Piezo Motion Corp, Discovery Technology International, Inc., MemoryMD US, MemoryMD – Russia and MemoryMD - Europe. All significant consolidated transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants.	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants.
The Effects of COVID-19	The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time.	The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At September 30, 2022 and December 31, 2021, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of September 30, 2022, and December 31, 2021, the Company had $1,621,012 and $277,989, respectively, in excess over the FDIC insurance limit.	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2021 and December 31, 2020, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of December 31, 2021 and December 31, 2020, the Company had $277,989 and $0, respectively, in excess over the FDIC insurance limit.
Inventory	nventory Inventory consists of raw material, works in progress and finished goods that are valued at lower of cost or market using the weighted average method.	I nventory Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method.
Property and Equipment	Property and Equipment Property, plant and equipment are carried at cost. Depreciation is provided on the straight-line method over the assets estimated service lives. Expenditures for maintenance and repairs are charged to expense in the period in which they are incurred, and betterments are capitalized. The cost of assets sold or abandoned, and the related accumulated depreciation are eliminated from the accounts and any gains or losses are reflected in the accompanying statements of operations of the respective period. The estimated useful lives range from 3 to 7 years.	Property and Equipment Property, plant and equipment are carried at cost. Depreciation is provided on the straight-line method over the assets estimated service lives. Expenditures for maintenance and repairs are charged to expense in the period in which they are incurred, and betterments are capitalized. The cost of assets sold or abandoned and the related accumulated depreciation are eliminated from the accounts and any gains or losses are reflected in the accompanying statements of operations of the respective period. The estimated useful lives range from 3 to 7 years.
Intangible assets, net	Intangible assets, net Intangible assets are measured at cost less accumulated amortization and impairment losses, if any. Intangible assets are amortized on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Patents 15 years Licenses and trademarks 9 years Amortization expense is included in the consolidated income statement within general and administrative expenses. The asset is tested annually and during interim periods for impairment if there is a trigger for impairment.
Goodwill	Good will Goodwill represents the excess of the consideration transferred over the fair value of the net identifiable assets acquired. Goodwill is evaluated for impairment annually or whenever we identify certain triggering events or circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include, among other things, unexpected adverse business conditions, macro and reporting unit specific economic factors (for example, interest rate and foreign exchange rate fluctuations, and loss of key personnel), supply costs, unanticipated competitive activities, and acts by governments and courts.	Goodwill Goodwill represents the excess of the consideration transferred over the fair value of the net identifiable assets acquired. Goodwill is evaluated for impairment annually or whenever we identify certain triggering events or circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include, among other things, unexpected adverse business conditions, macro and reporting unit specific economic factors (for example, interest rate and foreign exchange rate fluctuations, and loss of key personnel), supply costs, unanticipated competitive activities, and acts by governments and courts.
Convertible Notes Payable	Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be at a discount to the common stock at the time of conversion. For certain notes, the conversion features are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred.	Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be a discount to the common stock at the time of conversion. Some of the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred.
Reverse Stock Split	Revenue Recognition The Company recognizes revenue under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, (“ASC 606”). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract  ● Step 3: Determine the transaction price   ● Step 4: Allocate the transaction price to the performance obligations in the contract   ● Step 5: Recognize revenue when the Company satisfies a performance obligation   In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606’s definition of a “distinct” good or service (or bundle of goods or services) if both of the following criteria are met: The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct), and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). The Company has determined that product delivery is the primary performance obligation, and as such recognizes revenues upon delivery to the customer. If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. When determining the transaction price, an entity must consider the effects of all of the following: ● Variable consideration   ● Constraining estimates of variable consideration   ● The existence of a significant financing component in the contract   ● Noncash consideration   ● Consideration payable to a customer   Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate. The Company recognizes revenue from the sale of NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. Primarily all revenues for the nine months ended September 30, 2022 are from the sale of medical devices purchased from Neurotech. Revenues for the nine months ended September 30, 2021 of $14,482 related to the sales of Piezo evaluation kits.	Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. All revenue for the years ended December 31, 2021 and 2020 is from the sale of medical devices purchased from Neurotech, a related party.
Research and Development	Research and Development Costs The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the three and nine months ended September 30, 2022 were $56,684 and $224,405, respectively. Research and development costs recognized in the statement of operations for the three and nine months ended September 30, 2021 were $48,282 and $147,324, respectively.	Research and Development The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the years ended December 31, 2021 and 2020 were $329,452 and $210,706, respectively.
Sales and Marketing	Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the three and nine months ended September 30, 2022 were $165,414 and $570,666, respectively. Advertising and marketing costs recognized in the statement of operations for the three and nine months ended September 30, 2021 were $260,832 and $498,583, respectively.	Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the years ended December 31, 2021 and 2020 were $1,041,575 and $197,372, respectively.
Stock-based Compensation	Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.	Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the three and nine months ended September 30, 2022 and 2021, 1,873,406, and 0 anti-dilutive securities were excluded from the computation, respectively.	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the years ended December 31, 2021 and 2020, 84,193 and 0, respectively, of anti-dilutive securities were excluded from the computation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. As of September 30, 2022, the Company had a Level 3 financial instrument related to the derivative liabilities related to the issuance of convertible debt and warrants. The Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2021.	Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2021 and 2020.
Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis	Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of September 30, 2022. Liabilities Amounts Level 1 Level 2 Level 3 Derivative liability – conversion feature $ 1,159,000 $ - $ - $ 1,159,000 Derivative liability – warrants 698,351 - - 698,351 Total $ 1,857,351 $ - $ - $ 1,857,351
Income Taxes	Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of September 30, 2022, and December 31, 2021, the Company had no unrecognized uncertain income tax positions.	Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of December 31, 2021, and December 31, 2020, the Company had no unrecognized uncertain income tax positions.
Reclassification	Reclassification Certain prior years balances have been reclassified to conform to current year presentation.	Reclassification Certain prior years balances have been reclassified to conform to current year presentation.
Recent Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption.	Recent Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its consolidated financial statements.

Organization and Nature of Op_2

Organization and Nature of Operations (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization and Nature of Operations [Abstract]
Schedule of purchase price of the acquisition	Allocation Tangible Assets Acquired: Net working capital $ (1,186,622 ) Right of use asset 40,093 Lease liability (46,970 ) Net Tangible Assets Acquired $ (1,193,499 ) Intangible Assets Acquired: Licenses and trademarks Brain Scientific Trade Name 133,000 MemoryMD Trade Name 504,000 NeuroCap Trade Name 188,000 Neuro EEG Trade Name 11,000 Patent products NeuroCap Developed Technology 10,242,000 NeuroEEG Developed Technology 35,000 Net Intangible Assets Acquired $ 11,113,000 Total Fair Value of Assets Acquired $ 9,919,501 Consideration: Fair value of equity received 7,240,222 Liabilities assumed 2,987,152 Loans forgiven 605,311 Total consideration $ 10,832,685 Goodwill $ 913,184	Tangible Assets Acquired:   Allocation Net working capital (1,186,622 ) Right of use asset 40,093 Lease liability (46,970 ) Net Tangible Assets Acquired $ (1,193,499 )   Intangible Assets Acquired: Brain Scientific Trade Name 133,000 MemoryMD Trade Name 533,000 Neurocap Trade Name 188,000 Neuro EEG Trade Name 11,000 Customer Relationships (29,000 ) NeuroCap Developed Technology 10,242,000 NeuroEEG Developed Technology 35,000 Total Fair Value of Assets Acquired $ 11,113,000   Consideration: Fair value of equity received 7,240,222 Liabilities assumed 2,978,152 Loans forgiven 605,311 Goodwill $ 913,184

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of straight-line basis over their estimated useful lives	Patents 15 years Licenses and trademarks 9 years
Schedule of fair value on a recurring basis	Liabilities Amounts Level 1 Level 2 Level 3 Derivative liability – conversion feature $ 1,159,000 $ - $ - $ 1,159,000 Derivative liability – warrants 698,351 - - 698,351 Total $ 1,857,351 $ - $ - $ 1,857,351

Inventory (Tables)

Inventory (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Inventory [Abstract]
Schedule of inventory	September 30, December 31, Raw materials $ 76,379 $ 93,190 Works in progress 11,911 11,857 Finished goods 37,842 41,043 Total $ 126,132 $ 146,090	December 31, December 31, Raw materials $ 93,190 $ 20,608 Parts 11,857 2,349 Finished goods 41,043 21,947 Total $ 146,090 $ 44,904

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets [Abstract]
Schedule of prepaid expenses and other current assets	September 30, December 31, Prepaid Expenses $ 145,734 $ - Prepaid insurance 119,331 105,900 Other prepaid expenses 11,352 46,170 Lease deposits 14,378 14,378 Other assets - 10 Total $ 290,795 $ 166,458	December 31, December 31, Prepaid insurance $ 105,900 $ - Other prepaid expenses 46,170 7,000 Lease deposits 14,378 5,000 Other assets 10 - Total $ 166,458 $ 12,000

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property and Equipment [Abstract]
Schedule of property and equipment, net	September 30, December 31, Machinery and equipment $ 204,143 $ 176,678 Leasehold improvements 12,283 12,283 216,426 188,961 Less: Accumulated depreciation (91,686 ) (65,982 ) Total $ 124,740 $ 122,979	December 31, December 31, Computer equipment $ - $ 4,164 Machinery and equipment 176,678 121,433 Leasehold improvements 12,283 5,000 188,961 130,597 Less: Accumulated depreciation (65,982 ) (38,855 ) Total $ 122,979 $ 91,742

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Intangible Assets, Net [Abstract]
Schedule of acquired intangible assets	September 30, December 31, Average Patent products $ 10,277,000 $ 10,277,000 15.4 Licenses and trademarks 836,000 836,000 9 Intangible assets $ 11,113,000 $ 11,113,000 Less: Accumulated amortization (769,462 ) (192,423 ) Total $ 10,343,538 $ 10,920,577	Preliminary     Average   Fair   Estimated Life Patent products $  10,277,000 3.3 - 15.4 Licenses and trademarks   865,000 9 Customer/distribution list   (29,000) 12.5 $ 11,113,000     Accumulated amortization (192,423 ) Total 10,920,577
Schedule of allocation of purchase price of the acquisition		Tangible Assets Acquired: Allocation  Net working capital $ (1,186,622 ) Right of use asset 40,093 Lease liability (46,970 ) Net Tangible Assets Acquired $ (1,193,499 )        Intangible Assets Acquired:      Brain Scientific trade name $ 133,000 MemoryMD trade name 533,000 NeuroCap trade name 188,000 NeuroEEG trade name 11,000 Customer relationships (29,000 ) NeuroCap developed technology 10,242,000 NeuroEEG developed technology 35,000 Total Fair Value of Assets Acquired $ 11,113,000        Consideration:      Fair value of equity received 7,240,222 Liabilities assumed 2,978,152 Loans forgiven 605,311 Goodwill $ 913,184

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounts Payable and Accrued Expenses [Abstract]
Schedule of accounts payable	September 30, December 31, Trade payables $ 1,143,649 $ 1,101,028 Accrued payroll and related expenses 1,380,194 1,593,925 Accrued expenses 122,311 255,820 Customer deposits 6,882 36,491 Total $ 2,653,036 $ 2,987,264	December 31, December 31, Trade payables $ 1,101,028 $ 398,155 Accrued payroll and related expenses 1,593,925 997,410 Accrued expenses 255,820 48,911 Customer deposits 36,491 - Total $ 2,987,264 $ 1,444,476

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Financial Instruments [Abstract]
Schedule of conversion feature derivative valuations	Inception September 30, Common stock price $ 25.5 $ 10.2 Exercise price $ 28.05-30.6 28.05-30.6 Expected volatility 100.0 % 92.0-100.0 % Risk free rate 2.3-3.0 % 3.3-4.0 % Expected dividend yield 0 % 0 % Expected term (years) 0.55-1.25 0.25-0.95 Discount rate 37.7 % 37.7 % PV factor 0.67-0.84 0.80
Schedule of warrant derivative valuations	Inception September 30, Common stock price $ 25.5 $ 10.2 Expected volatility 100.0 % 98.0 % Expected term (years) 6.05 5.5 Risk free rate 3.5 % 4.0 % Expected dividend yield 0 % 0 %
Schedule of derivative liabilities	Conversion Feature Warrants Total Balance at December 31, 2021 - - - Issuance – June 13, 2022 $ 1,610,000 $ 1,622,399 $ 3,232,399 Movement in fair value (451,000 ) (924,048 ) (1,375,048 ) Balance at September 30, 2022 $ 1,159,000 $ 698,351 $ 1,857,351

Leases (Tables)

Leases (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Schedule of operating maturity of lease liability	2022 $ 21,491 2023 88,325 2024 7,378 Total undiscounted finance lease payments 117,194 Less: Imputed interest (7,032 ) Present value of finance lease liabilities $ 110,162	Maturity of operating lease liabilities for the following fiscal years: 2022 $  118,452 2023 88,325 2024 7,379 Total undiscounted finance lease payments 214,156 Less: Imputed interest 18,475 Present value of finance lease liabilities $  195,681
Schedule of supplemental balance sheet information related to the lease	Operating lease right-of-use asset $ 107,617 Lease liability, current portion 81,012 Lease liability, long-term 29,150 Total operating lease liability $ 110,162	Operating lease right-of-use asset $ 191,702 Lease liability, current portion 104,592 Lease liability, long-term 91,089 Total operating lease liability $ 195,681

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stockholders' Deficit [Abstract]
Schedule of warrant activity	Number of Weighted Weighted Aggregate Warrants Shares Price Term Value Balance Outstanding, December 31, 2021 108,922 $ 38.25 6.85 $ 304,799 Granted 246,024 7.65 5.20 - Forfeited (554 ) - - - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2022 354,392 $ 17.0 5.45 - Exercisable, September 30, 2022 90,719 $ 32.3 6.83 -	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2019 5,908 $ 48.45 3.98 $ 201,125 Granted 41,540 86.7 3.90 150,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 47,448 $ 82.45 3.39 $ 351,125 Granted 70,332 16.15 9.52 304,799 Forfeited - - - - Exercised - - - - Expired (8,858 ) 102.0 1.73 - Balance Outstanding, December 31, 2021 108,922 $ 38.25 6.85 $ 304,799 Exercisable, December 31, 2021 108,922 $ 27.2 6.85 $ 304,799
Schedule of option activity	Number of Weighted Weighted Aggregate Options Shares Price Term Value Balance Outstanding, December 31, 2021 138,275 $ 30.6 9.47 $ 196,825 Granted 316,168 11.05 5.00 - Forfeited (5,602 ) 17.85 9.20 - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2022 448,841 $ 17.0 6.15 - Exercisable, September 30, 2022 415,819 $ 17.0 5.98 -	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2019 11,765 $ 63.75 9.05 $ 150,000 Granted 9,412 $ 63.75 10.00 120,000 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 21,177 $ 63.75 8.51 $ 270,000 Granted 118,007 25.50 9.82 196,825 Forfeited (909 ) 127.50 9.12 Exercised Expired Balance Outstanding, December 31, 2021 138,275 $ 30.6 9.47 $ 196,825 Exercisable, December 31, 2021 76,908 $ 18.7 9.14 $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
Schedule of deferred tax assets liabilities	For the Years Ended 2021 2020 Net operating loss carry forwards $ 4,181,841 $ 2,252,985 Share-based compensation 806,997 90,110 Accrued expenses 301,422 19,009 Intangible assets 100,736 107,187 Fixed assets (29,877 ) (23,039 ) Valuation allowance (5,361,119 ) (2,446,252 ) Net Deferred Tax Asset $ - $ -
Schedule of reconciliation statutory federal income tax	For the Years Ended 2021 2020 Statutory federal tax rate 21.0 % 21.0 % State tax expense 4.7 % 4.3 % Acquired deferred tax assets 7.8 % - % PPP loan forgiveness 0.3 % - % Change in tax rate (0.9 )% - % Amortization (0.4 )% - % Other permanent items (0.3 )% (0.1 )% Valuation allowance (32.2 )% (25.2 )% Provision for income taxes - % - %

Organization and Nature of Op_3

Organization and Nature of Operations (Details) - shares	Sep. 30, 2022	Dec. 31, 2021	Jun. 11, 2021
Organization and Nature of Operations (Textual)
Shares of common stock			347,333
Common stock shares issued	0.03	0.03

Organization and Nature of Op_4

Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Consideration:
Fair value of equity received	$ 7,240,222
Liabilities assumed	2,987,152
Loans forgiven	605,311
Total consideration	10,832,685
Goodwill	913,184	$ 913,184
Merger Agreement [Member]
Tangible Assets Acquired:
Net Tangible Assets Acquired	(1,193,499)	(1,193,499)
Licenses and trademarks
Net Intangible Assets Acquired	11,113,000
Patent products
Total Fair Value of Assets Acquired	9,919,501	11,113,000
Consideration:
Fair value of equity received		7,240,222
Liabilities assumed		2,978,152
Loans forgiven		605,311
Goodwill		913,184
Net working capital [Member] | Merger Agreement [Member]
Tangible Assets Acquired:
Net Tangible Assets Acquired	(1,186,622)	(1,186,622)
Right of Use Asset [Member] | Merger Agreement [Member]
Tangible Assets Acquired:
Net Tangible Assets Acquired	40,093	40,093
Lease Liability [Member] | Merger Agreement [Member]
Tangible Assets Acquired:
Net Tangible Assets Acquired	(46,970)	(46,970)
Brain Scientific Trade Name [Member] | Merger Agreement [Member]
Licenses and trademarks
Net Intangible Assets Acquired	133,000
Patent products
Total Fair Value of Assets Acquired		133,000
MemoryMD Trade Name [Member] | Merger Agreement [Member]
Licenses and trademarks
Net Intangible Assets Acquired	504,000
Patent products
Total Fair Value of Assets Acquired		533,000
Neurocap Trade Name [Member] | Merger Agreement [Member]
Licenses and trademarks
Net Intangible Assets Acquired	188,000
Patent products
Total Fair Value of Assets Acquired		188,000
Neuro EEG Trade Name [Member] | Merger Agreement [Member]
Licenses and trademarks
Net Intangible Assets Acquired	11,000
Patent products
Total Fair Value of Assets Acquired		11,000
NeuroEEG Developed Technology [Member] | Merger Agreement [Member]
Licenses and trademarks
Net Intangible Assets Acquired	35,000
Patent products
Total Fair Value of Assets Acquired		35,000
NeuroCap Developed Technology [Member] | Merger Agreement [Member]
Licenses and trademarks
Net Intangible Assets Acquired	$ 10,242,000
NeuroCap Developed Technology [Member] | Merger Agreement [Member] | Merger Agreement [Member]
Patent products
Total Fair Value of Assets Acquired		$ 10,242,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash, FDIC insured amount	$ 250,000		$ 250,000		$ 250,000
Cash, uninsured amount	1,621,012		1,621,012		277,989	$ 0
Revenues	11,432	$ 5,275	209,484	$ 14,482	265,747	93,664
Research and development expense	56,684	48,282	224,405	147,324	329,452	210,706
Advertising and marketing costs	$ 165,414	$ 260,832	$ 570,666	$ 498,583	$ 1,041,575	$ 197,372
Anti-dilutive securities shares (in Shares)	1,873,406	0	1,873,406	0	84,193	0
Income tax benefit, percentage			50%		50%
Minimum [Member]
Accounting Policies [Abstract]
Estimated useful live			3 years		3 years
Maximum [Member]
Accounting Policies [Abstract]
Estimated useful live			7 years		7 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of straight-line basis over their estimated useful lives	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Patents	15 years
Licenses and trademarks	9 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of fair value on a recurring basis	9 Months Ended
	Sep. 30, 2022 USD ($)
Accounting Policies [Abstract]
Derivative liability – conversion feature	$ 1,159,000
Derivative liability – warrants	698,351
Total	1,857,351
Level 1 [Member]
Accounting Policies [Abstract]
Derivative liability – conversion feature
Derivative liability – warrants
Total
Level 2 [Member]
Accounting Policies [Abstract]
Derivative liability – conversion feature
Derivative liability – warrants
Total
Level 3 [Member]
Accounting Policies [Abstract]
Derivative liability – conversion feature	1,159,000
Derivative liability – warrants	698,351
Total	$ 1,857,351

Going Concern (Details)

Going Concern (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Going Concern [Abstract]
Revenues	$ 209,484	$ 265,747
Net loss	9,110,360	9,100,686
Net cash used in operations	$ 4,691,693	$ 5,794,792
Accumulated deficit	$31,389,283	$22,278,923
Working capital	$ 4,353,257
Working capital deficit		$ 2,874,735
Stockholders’ deficit		$ 694,933

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Inventory [Abstract]
Raw materials	$ 76,379	$ 93,190	$ 20,608
Works in progress	11,911	11,857
Finished goods	37,842	41,043	21,947
Total	$ 126,132	$ 146,090	$ 44,904

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses And Other Current Assets [Abstract]
Long term prepaid insurance	$ 80,000	$ 95,000	$ 0

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid insurance	$ 145,734	$ 105,900
Prepaid production costs	119,331	105,900
Other prepaid expenses	11,352	46,170	$ 7,000
Lease deposits	14,378	14,378	5,000
Other assets		10
Total	$ 290,795	$ 166,458

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment [Abstract]
Depreciation expense	$ 8,635	$ 7,538	$ 25,704	$ 19,376	$ 27,410	$ 17,353

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment, net - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 216,426	$ 188,961	$ 130,597
Less: Accumulated depreciation	(91,686)	(65,982)	(38,855)
Property and Equipment, net	124,740	122,979	91,742
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment	204,143	176,678	121,433
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment	$ 12,283	$ 12,283	$ 5,000

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Intangible Assets, Net [Abstract]
Amortization expenses	$ 192,365		$ 577,039

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details) - Schedule of acquired intangible assets - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 11,113,000	$ 11,113,000
Average Estimated Life	9 years
Less: Accumulated amortization	$ (769,462)	(192,423)
Total	10,343,538	10,920,577
Patent products [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 10,277,000	10,277,000
Average Estimated Life	15 years 4 months 24 days
Licenses and trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 836,000	$ 836,000
Average Estimated Life	9 years

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - Schedule of accounts payable - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Accounts Payable [Abstract]
Trade payables	$ 1,143,649	$ 1,101,028	$ 398,155
Accrued payroll and related expenses	1,380,194	1,593,925	997,410
Accrued expenses	122,311	255,820	48,911
Customer deposits	6,882	36,491
Total	$ 2,653,036	$ 2,987,264	$ 1,444,476

Accrued Director's fees (Detail

Accrued Director's fees (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accrued director's fees [Abstract]
Accrued director’s fees amount	$ 75,000	$ 75,000

Convertible Notes Payable _ S_2

Convertible Notes Payable – Short Term (Details)		1 Months Ended					3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 13, 2022	Apr. 20, 2022 shares	Dec. 30, 2021	Dec. 21, 2021 USD ($)	Apr. 21, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares $ / item	Sep. 30, 2022 USD ($) $ / shares $ / item shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 28, 2021 USD ($)
Convertible Notes Payable – Short Term (Details) [Line Items]
Converted notes								$ 250,000
Accrued interest								33,000
Agreement paid							$ 30,000	30,000		$ 33,600
Principal balance								90,000
Accrued interest							33,000	33,000	$ 4,328,407
Paid principal amount								30,000
Balance amount							$ 90,000	$ 90,000
Conversion price (in Dollars per share) | $ / shares							$ 23.8	$ 23.8
Price per share percentage								80%
Ownership limitation percentage								9.99%
Outstanding balance percentage								130%
Lowest trade								65%
Exercise price (in Dollars per Item) | $ / item							106.25	106.25
Warrant term								5 years
Principle amount				$ 900,000	$ 125,000
Warrant purchase shares (in Shares) | shares					8,824
Exercise price (in Dollars per share) | $ / shares									$ 1
Outstanding principal balance									$ 20,000
Securities purchase agreement description	On June 13, 2022, the Company consummated the first closing of a private placement offering whereby the Company entered into a Securities Purchase Agreement (SPA), dated as of June 13, 2022 with thirteen accredited investors, pursuant to which the investors purchased from the Company, for an aggregate purchase price of $5,110,000, (i) 10% Original Issue Discount Senior Secured Convertible Debentures (the “2022 Notes”), in the principal amount of $5,659,500 and (ii) 222,311 warrants to purchase shares of common stock of the Company at the same price as the debt conversion price. In addition, 23,713 warrants were issued to the book-runner of this offering (together with the 222,311 investor warrants – the “2022 warrants”). The 2022 Notes mature on June 13, 2023 and bear interest at an annual rate of 10%.
Debt discount (in Shares) | shares								4,470,289
Interest expense							$ 553,200	$ 633,312
Discount amount							3,836,977	3,836,977
Gross proceeds								$ 5,000,000
Per share (in Dollars per share) | $ / shares								$ 21.25
Voluntary conversion percentage								75%
Original investment amount								10%
Debt assumed									1,540,508
Investor amount									2,950,000
Proceeds									2,850,000
Dept discount									$ 83,364
Warrant share amount description									Each holder of the 2021 Notes, provided that the note is still then outstanding, will be issued, on the earlier of (i) the date, if any, upon which the Company’s common stock is listed for trading on the NASDAQ stock exchange (the “Uplist”), and (ii) the date that is eighteen months from the date of issuance, a warrant to purchase an amount of shares of the Company’s common stock, equal to such holder’s Warrant Share Amount. For purposes of the foregoing, a holder’s “Warrant Share Amount” means (i) if such Warrant is issued in connection with the Uplist, one half of the initial principal balance of such Holder’s Note at issuance divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the closing price for the Company’s common stock on the trading day prior to the date of the Uplist, and (ii) if such Warrant is issued otherwise than in connection with the Uplist, the initial principal balance of such Holder’s Note, divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the volume weighted average price (“VWAP”) for the Company’s common stock over the five consecutive trading days immediately preceding the date that is eighteen months from the date of issuance. The 2021 Notes contain mandatory and voluntary conversion features as detailed in the agreement.
Principal amount				$ 900,000				$ 2,000,000
Notes principal outstanding									$ 9,718,915
Accrued interest percentage									10%
Original investment amount									50%
Warrants term								4 years
Warrants								$ 21.25
Common Stock [Member]
Convertible Notes Payable – Short Term (Details) [Line Items]
Ownership limitation percentage								4.99%
Shares issued (in Shares) | shares		3,380
Assumed convertible debt [Member]
Convertible Notes Payable – Short Term (Details) [Line Items]
Outstanding convertible debt							$ 891,133	$ 891,133	$ 891,133
Convertable notes payable amount paid									574,133
Increasing debt									20,000
Convertible debt									337,000
2019 Note [Member]
Convertible Notes Payable – Short Term (Details) [Line Items]
Original principal amount						$ 275,000
Purchase of common stock (in Shares) | shares						1,176
Interest charged percentage						8%
Long term debt, description			On December 30, 2021, the Company signed an allonge amending the Note extending the maturity date to April 30, 2022 and amending the outstanding balance and payment schedule to provide for two equal payments of $60,000 on March 31, 2022 and April 30, 2022. On March 31, 2022 the Company signed an allonge amending the Note, extending the maturity date to December 31, 2022 and amended the outstanding balance and payment schedule to provide for seven monthly payments of $10,000 plus interest at the rate of 14% per annum. The first monthly payment is payable on June 30, 2022. A final payment of $50,000 plus interest is due upon maturity.
Convertible Grid Notes [Member]
Convertible Notes Payable – Short Term (Details) [Line Items]
Principle amount					$ 125,000
Warrant purchase shares (in Shares) | shares					8,824
Exercise price (in Dollars per share) | $ / shares					$ 68
Warrant exercise price per share (in Dollars per share) | $ / shares					$ 68
Debt interest rate					12%			12%
Outstanding principal balance									250,000
Accrued interest					$ 28,032				$ 28,032

Derivative Financial Instrume_3

Derivative Financial Instruments (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Derivative Financial Instruments [Abstract]
Derivative liabilities conversion feature	$ 1,159,000
Fair value of derivative liabilities of warrants	$ 698,351

Derivative Financial Instrume_4

Derivative Financial Instruments (Details) - Schedule of conversion feature derivative valuations - $ / shares	9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Derivative Financial Instruments (Details) - Schedule of conversion feature derivative valuations [Line Items]
Common stock price (in Dollars per share)	$ 25.5	$ 10.2
Expected volatility	100%	98%
Risk free rate	3.50%	4%
Expected dividend yield	0%	0%
Expected term (years)	6 years 18 days	5 years 6 months
Discount rate	37.70%	37.70%
PV factor (in Dollars per share)		$ 0.8
Minimum [Member]
Derivative Financial Instruments (Details) - Schedule of conversion feature derivative valuations [Line Items]
Exercise price (in Dollars per share)	$ 28.05	$ 28.05
Expected volatility		92%
Risk free rate	2.30%	3.30%
Expected term (years)	6 months 18 days	3 months
PV factor (in Dollars per share)	$ 0.67
Maximum [Member]
Derivative Financial Instruments (Details) - Schedule of conversion feature derivative valuations [Line Items]
Exercise price (in Dollars per share)	$ 30.6	$ 30.6
Expected volatility		100%
Risk free rate	3%	4%
Expected term (years)	1 year 3 months	11 months 12 days
PV factor (in Dollars per share)	$ 0.84

Derivative Financial Instrume_5

Derivative Financial Instruments (Details) - Schedule of warrant derivative valuations - $ / shares	9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Schedule of Warrant Derivative Valuations [Abstract]
Common stock price (in Dollars per share)	$ 25.5	$ 10.2
Expected volatility	100%	98%
Expected term (years)	6 years 18 days	5 years 6 months
Risk free rate	3.50%	4%
Expected dividend yield	0%	0%

Derivative Financial Instrume_6

Derivative Financial Instruments (Details) - Schedule of derivative liabilities	9 Months Ended
	Sep. 30, 2022 USD ($)
Derivative Financial Instruments (Details) - Schedule of derivative liabilities [Line Items]
Balance at December 31, 2021
Issuance – June 13, 2022	3,232,399
Movement in fair value	(1,375,048)
Balance at September 30, 2022	1,857,351
Conversion Feature [Member]
Derivative Financial Instruments (Details) - Schedule of derivative liabilities [Line Items]
Balance at December 31, 2021
Issuance – June 13, 2022	1,610,000
Movement in fair value	(451,000)
Balance at September 30, 2022	1,159,000
Warrants [Member]
Derivative Financial Instruments (Details) - Schedule of derivative liabilities [Line Items]
Balance at December 31, 2021
Issuance – June 13, 2022	1,622,399
Movement in fair value	(924,048)
Balance at September 30, 2022	$ 698,351

Notes Payable (Details)

Notes Payable (Details) - USD ($)	1 Months Ended
	Dec. 28, 2021	Dec. 28, 2020	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes Payable (Details) [Line Items]
Interest payment term		1 year
Installment amount		$ 56,000
Debt instrument amount		300,000			$ 300,000
Interest payment amount	$ 33,600			$ 30,000
Aggregate payment	$ 184,800
Exercise price (in Dollars per share)			$ 25.5	$ 10.2
Warrant [Member]
Notes Payable (Details) [Line Items]
Exercise price (in Dollars per share)				$ 102
Securities Purchase Agreement [Member]
Notes Payable (Details) [Line Items]
Aggregate purchase payment		$ 300,000				$ 265,000
Purchase of aggregate shares (in Shares)		5,882
Additional commitment fee		$ 2,941
Fixed interest rate		12%
Securities Purchase Agreement [Member] | Warrant [Member]
Notes Payable (Details) [Line Items]
Purchase of aggregate shares (in Shares)		2,941

Notes Payable _ Related Party (

Notes Payable – Related Party (Details)		9 Months Ended		12 Months Ended
	Aug. 01, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 RUB (₽)	Dec. 31, 2021 USD ($)	Oct. 01, 2022 USD ($)	Jun. 01, 2022 USD ($)	May 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 09, 2022	Oct. 01, 2021 USD ($)
Notes Payable – Related Party (Details) [Line Items]
Related party loans										$ 155,530
Interest rate									9%
Accrued interest								$ 53,000
Payment of accrued interest	$ 49,000
Debt instrument payment				$ 9,718,915	$ 49,000		$ 53,000
Repaid outstanding principal		$ 106,000
Prepaid principal due		1,598
Prepaid principal due balance		47,402
Outstanding loan		596	₽ 34,400
Related party loans				155,989
Accrued interest		$ 33,000		$ 4,328,407
Forecast [Member]
Notes Payable – Related Party (Details) [Line Items]
Interest rate									9%
Accrued interest						$ 53,000		$ 53,000
Payment of accrued interest	$ 49,000

Leases (Details)

Leases (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 01, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Leases (Details) [Line Items]
Finance lease, description				The term of the lease is for a period of two years commencing on February 1, 2021 and ending on February 1, 2023. The rent is $6,530 per month for year 1, $6,726 per month for year 2 and $6,928 per month for year 3. The Company will account for the lease under ASC 842 whereby the operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date.		The term of the lease is for a period of two years commencing on February 1, 2021 and ending on February 1, 2023. The rent is $6,530 per month for year 1, $6,726 per month for year 2 and $6,928 per month for year 3. The Company will account for the lease under ASC 842 whereby the operating lease right-of-use assets and liabilities are recognized at the present value of the future lease payments at the lease commencement date.
Lease terms of office space		2 years		2 years		2 years
Lease amount	$ 1,660
Weighted-average remaining lease term				1 year 10 months 24 days		1 year 10 months 24 days
Weighted-average remaining discount rate		10.32%		10.32%		10.32%
Operating leases expenses						$ 69,300
Operating lease right of use assets		$ 107,617		$ 107,617		69,632
Operating lease		$ 4,025,461	$ 1,733,614	8,165,978	$ 3,511,991	8,739,705	$ 2,819,390
General and administrative expenses [Member]
Leases (Details) [Line Items]
Operating leases expenses				$ 64,490	$ 0
Operating lease						$ 83,469	$ 0

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating maturity of lease liability - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule of operating maturity of lease liability [Abstract]
2022	$ 21,491	$ 118,452
2023	88,325	88,325
2024	7,378	7,379
Total undiscounted finance lease payments	117,194	214,156
Less: Imputed interest	(7,032)
Present value of finance lease liabilities	$ 110,162	$ 195,681

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of supplemental balance sheet information related to the lease - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of supplemental balance sheet information related to the lease [Abstract]
Operating lease right-of-use asset	$ 107,617	$ 191,702
Lease liability, current portion	81,012	104,592
Lease liability, long-term	29,150	91,089
Total operating lease liability	$ 110,162	$ 195,681

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)

1 Months Ended

9 Months Ended

12 Months Ended

Dec. 10, 2021

Dec. 10, 2021

Nov. 15, 2021

Oct. 21, 2021

Oct. 01, 2021

Jul. 15, 2021

Oct. 15, 2020

Jan. 14, 2019

Aug. 19, 2022

May 19, 2022

Nov. 15, 2021

Jan. 30, 2020

Sep. 21, 2018

Dec. 31, 2022

Sep. 30, 2022

Dec. 31, 2021

Jan. 31, 2022

Dec. 31, 2020

Stockholders' Deficit (Textual)

Preferred stock, shares authorized

10,000,000

10,000,000

10,000,000

Preferred stock, par value

$ 0.001

$ 0.001

$ 0.001

Common stock, authorized

750,000,000

750,000,000

Common stock, par value

$ 0.001

$ 0.001

$ 0.001

Voting rights

one

one

Shares issued

4,243

Outstanding payables

$ 129,850

Equity incentive plan, description

The vesting period, term and exercise price will be determined at the time of the grant. An aggregate of up to 41,176 of the Company’s common stock was reserved for issuance under the 2018 Plan. On July 15, 2021 the Company’s board of directors increased the number of shares of common stock authorized for grant from 41,176 to 94,118. As of March 31, 2022, the Company has granted and has 85,285 options outstanding, as well as 1,269 shares of restricted common stock issued under the 2018 Plan.

Purchase an aggregate, description

the Board of Directors approved the issuance of options to purchase an aggregate of 31,979 shares of common stock to the certain employees of the Company. The options have an exercise price of $17.85 per share with vesting terms of one quarter vesting on June 10, 2022 and the remainder monthly ratably through December 10, 2023. The options will expire on December 11, 2031. The aggregate fair value of $472,975 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 116.90%, (iii) risk free rate of 1.26% (iv) dividend rate of zero, (v) stock price of $17.85, and (vi) exercise price of $17.85. These options were amended on December 30, 2021 adjusting the vesting schedule to vest equally at the end of each quarter in 2022. As the share price had increased on the amendment date, the amendment resulted in an increase to the aggregate fair value of $111,166. The increased fair value along with the unamortized portion of the original fair value will be amortized over the amended vesting schedule. A total of $26,574 was recorded during the year ended December 31, 2021.

the Board of Directors approved the issuance of options to purchase an aggregate of 31,979 shares of common stock to the certain employees of the Company. The options have an exercise price of $17.85 per share with vesting terms of one quarter vesting on June 10, 2022 and the remainder monthly ratably through December 10, 2023. The options will expire on December 11, 2031. The aggregate fair value of $472,975 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 116.90%, (iii) risk free rate of 1.26% (iv) dividend rate of zero, (v) stock price of $17.85, and (vi) exercise price of $17.85. These options were amended on December 30, 2021 adjusting the vesting schedule to vest equally at the end of each quarter in 2022. As the share price had increased on the amendment date, the amendment resulted in an increase to the aggregate fair value of $111,166. The increased fair value along with the unamortized portion of the original fair value will be amortized over the amended vesting schedule. A total of $26,574 was recorded during the year ended December 31, 2021

the Board of Directors approved the issuance of options to purchase an aggregate of 17,039 shares of common stock to the directors of the Company. The options have an exercise price of $24.65 per share and vest per days in service as members of the board of directors during the quarter, at the end of the quarter with the final quarterly vesting quarter end of December 31, 2022. The options will expire on December 11, 2031. The aggregate fair value of $341,793 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5.04 years, (ii) volatility of 115.8%, (iii) risk free rate of 1.25% (iv) dividend rate of zero, (v) stock price of $24.65, and (vi) exercise price of $24.65. The expense will be amortized over the vesting period and a total of $28,254 was recorded during the year ended December 31, 2021.

the Board of Directors approved the issuance of options to purchase an aggregate of 14,332 shares of common stock to the CEO. The options have an exercise price of $33.15 per share with vesting terms of 3,583 vesting on April 21, 2022 and the remainder monthly ratably through October 21, 2023. The options will expire on October 21, 2031. The aggregate fair value of $372,384 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 4.65 years, (ii) volatility of 113.90%, (iii) risk free rate of 1.22% (iv) dividend rate of zero, (v) stock price of $33.15, and (vi) exercise price of $33.15. These options were amended on December 10, 2021 and December 30, 2021 adjusting the exercise price to $17.85 and the vesting schedule to vest equally at the end of each quarter in 2022. The expense will be amortized over the amended vesting period and a total of $36,667 was recorded during the year ended December 31, 2021.

the Board of Directors approved the issuance of options to purchase an aggregate of 52,990 shares of common stock to an executive and a director. The options have an exercise price of $29.75 per share and vested immediately upon issuance. The options will expire on October 1, 2031. The aggregate fair value of $1,270,188 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115%, (iii) risk free rate of 0.93% (iv) dividend rate of zero, (v) stock price of $29.75, and (vi) exercise price of $29.75. The expense of 1,270,188 was recorded in full upon issuance.

the Board of Directors approved the issuance of options to purchase an aggregate of 303,390 shares of common stock to certain employees of the Company. The options have an exercise price of $10.2 per share with varying vesting terms through August 10, 2023. The options will expire on August 19, 2027. The aggregate fair value of $2,346,000 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 100.0%, (iii) risk free rate of 3.10% (iv) dividend rate of zero, (v) stock price of $10.2, and (vi) exercise price of $10.2. The expense will be amortized over the vesting period and a total of $2,277,618 was recorded since issuance and through September 30, 2022.

the Board of Directors approved the issuance of options to purchase an aggregate of 12,778 shares of common stock to certain employees of the Company. The options have an exercise price of $26.35 per share with vesting terms of one quarter/half vesting on November 19, 2022 and the remainder monthly ratably through May 19, 2023. The options will expire on May 19, 2032. The aggregate fair value of $271,324 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115.0%, (iii) risk free rate of 2.80% (iv) dividend rate of zero, (v) stock price of $26.35, and (vi) exercise price of $26.35. The expense will be amortized over the vesting period and a total of $99,491 was recorded since issuance and through September 30, 2022.

the Board of Directors approved the issuance of options to purchase an aggregate of 17,039 shares of common stock to the directors of the Company. The options have an exercise price of $24.65 per share and vest per days in service as members of the board of directors during the quarter, at the end of the quarter with the final quarterly vesting quarter end of December 31, 2022. The options will expire on December 11, 2031. The aggregate fair value of $341,793 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5.04 years, (ii) volatility of 115.8%, (iii) risk free rate of 1.25% (iv) dividend rate of zero, (v) stock price of $24.65, and (vi) exercise price of $24.65. The expense will be amortized over the vesting period and a total of $28,254 was recorded during the year ended December 31, 2021.

the Board of Directors approved the issuance of options to purchase an aggregate of 9,412 shares of common stock to Boris Goldstein. The options have an exercise price of $63.75 per share which will vest ratably on a quarterly basis over a two-year period. The options will expire on January 30, 2029. The aggregate fair value of $51,757 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 76%, (iii) risk free rate of 1.57% (iv) dividend rate of zero, (v) stock price of $10.2, and (vi) exercise price of $63.75. The expense will be amortized over the vesting period and a total of $23,790 was recorded during the year ended December 31, 2020.

Stock option remaining value

$ 513,807

Stock based compensation

$ 280,369

Common stock issued

128

Tax withholdings

2,168

Expected life (years)

6 years 18 days

5 years 6 months

Volatility rate

100%

98%

Risk free interest rate

3.50%

4%

Dividend rate

0%

0%

Share price

$ 25.5

$ 10.2

Previously Reported [Member]

Stockholders' Deficit (Textual)

Common stock, authorized

200,000,000

200,000,000

Minimum [Member]

Stockholders' Deficit (Textual)

Expected life (years)

6 months 18 days

3 months

Volatility rate

92%

Risk free interest rate

2.30%

3.30%

Exercise price

$ 28.05

$ 28.05

Maximum [Member]

Stockholders' Deficit (Textual)

Expected life (years)

1 year 3 months

11 months 12 days

Volatility rate

100%

Risk free interest rate

3%

4%

Exercise price

$ 30.6

$ 30.6

Common Stock [Member]

Stockholders' Deficit (Textual)

Shares outstanding

1,240,094

590,857

2018 Equity Incentive Plan [Member]

Stockholders' Deficit (Textual)

Common stock are reserved for issuance

41,176

Option outstanding

21,176

Issue of shares for the services

3,929

2018 Equity Incentive Plan [Member] | Minimum [Member]

Stockholders' Deficit (Textual)

Common stock authorized for grant

3,500,000

2018 Equity Incentive Plan [Member] | Maximum [Member]

Stockholders' Deficit (Textual)

Common stock authorized for grant

8,000,000

Option [Member]

Stockholders' Deficit (Textual)

Remaining stock options will be amortized

$ 1,266,050

Non-Executive Officer [Member]

Stockholders' Deficit (Textual)

Granted restricted shares

3,437

Grant fair value per share

$ (1.67)

Amortized vesting period value

$ 487,931

Board of Directors [Member] | Option [Member]

Stockholders' Deficit (Textual)

Purchase of aggregate share

9,412

Aggregate fair value of options

$ 51,757

Expected life (years)

10 years

Volatility rate

76%

Risk free interest rate

1.57%

Dividend rate

0%

Share price

$ 10.2

Exercise price

$ 63.75

Boris Goldstein [Member] | Option [Member]

Stockholders' Deficit (Textual)

Description of options vesting period

The options have an exercise price of $63.75 per share which will vest ratably on a quarterly basis over a two-year period.

Expiration date

Jan. 30, 2029

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrants Number of Shares outstanding at beginning balance	108,922
Warrants Weighted Average Exercise Price outstanding at beginning balance	$ 38.25
Warrants Weighted Average Remaining Contractual Term outstanding at beginning balance	6 years 10 months 6 days
Warrants Warrant Aggregate Intrinsic Value outstanding at beginning	$ 304,799
Granted Number of Shares	246,024
Granted Weighted Average Exercise Price	$ 7.65
Granted Weighted Average Remaining Contractual Term	5 years 2 months 12 days
Granted Aggregate Intrinsic Value		$ 304,799	$ 150,000
Forfeited Number of Shares	(554)
Forfeited Weighted Average Exercise Price
Forfeited Weighted Average Remaining Contractual Term
Forfeited Aggregate Intrinsic Value
Exercised Number of Shares
Exercised Weighted Average Exercise Price
Exercised Weighted Average Remaining Contractual Term
Exercised Aggregate Intrinsic Value
Expired Number of Shares
Expired Weighted Average Exercise Price
Expired Weighted Average Remaining Contractual Term
Expired Aggregate Intrinsic Value
Warrants Number of Shares outstanding at ending balance	354,392	108,922
Warrants Weighted Average Exercise Price outstanding at ending balance	$ 17	$ 38.25
Warrants Weighted Average Remaining Contractual Term outstanding at ending balance	5 years 5 months 12 days
Warrants Warrant Aggregate Intrinsic Value outstanding at ending		$ 304,799
Warrants Number of Shares exercisable at ending	90,719
Warrants Weighted Average Exercise Price exercisable at ending	$ 32.3
Warrants Weighted Average Remaining Contractual Term exercisable at ending	6 years 9 months 29 days
Warrants Warrant Aggregate Intrinsic Value exercisable at ending

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of option activity - Options [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Deficit (Details) - Schedule of option activity [Line Items]
Option Number of Shares outstanding at beginning	138,275
Option Weighted Average Exercise Price outstanding	$ 30.6
Option Weighted Average Remaining Contractual Term outstanding at beginning	9 years 5 months 19 days		9 years 18 days
Option Aggregate Intrinsic Value outstanding at beginning	$ 196,825
Granted Number of Shares	316,168	118,007	9,412
Granted Weighted Average Exercise Price	$ 11.05	$ 25.5	$ 63.75
Granted Weighted Average Remaining Contractual Term	5 years	9 years 9 months 25 days	10 years
Granted Aggregate Intrinsic Value
Forfeited Number of Shares	(5,602)	(909)
Forfeited Weighted Average Exercise Price	$ 17.85	$ 127.5
Forfeited Weighted Average Remaining Contractual Term	9 years 2 months 12 days	9 years 1 month 13 days
Forfeited Aggregate Intrinsic Value
Exercised Number of Shares
Exercised Weighted Average Exercise Price
Exercised Weighted Average Remaining Contractual Term
Exercised Aggregate Intrinsic Value
Expired Number of Shares
Expired Weighted Average Exercise Price
Expired Weighted Average Remaining Contractual Term
Expired Aggregate Intrinsic Value
Option Number of Shares outstanding at ending	448,841	138,275
Option Weighted Average Exercise Price outstanding at ending	$ 17	$ 30.6
Option Weighted Average Remaining Contractual Term outstanding at ending	6 years 1 month 24 days
Option Aggregate Intrinsic Value outstanding at ending		$ 196,825
Option Number of Shares exercisable at ending	415,819	76,908
Option Weighted Average Exercise Price exercisable at ending	$ 17	$ 18.7
Option Weighted Average Remaining Contractual Term exercisable at ending	5 years 11 months 23 days	9 years 1 month 20 days
Option Aggregate Intrinsic Value exercisable at ending

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		3 Months Ended		9 Months Ended	12 Months Ended		21 Months Ended
	Nov. 12, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2023
Related Party Transactions [Abstract]
Rent expense		$ 9,900	$ 9,900	$ 29,700	$ 39,600	$ 29,700	$ 29,700
Service percentage	10%				10%
Training platform development	$ 4,750				$ 4,750
Rent expense paid					69,300
Loans payable					$ 155,989

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 18, 2022	Sep. 30, 2022
Commitments and Contingencies (Textual)
Commitments and contingencies description	On February 18, 2022, the Company signed an outsourced manufacturing agreement with Bioana, S.A.P.I. DE C.V. The agreement is for three years, ending December 31, 2024 for a minimum order quantity of 10,000 NeuroCaps per annum. Unit cost for the NeuroCap is fixed for the first year ending December 31, 2022. The approximate cost for this agreement in 2022 is $350,000. The manufacturing agreement will renew annually unless terminated in writing by one of the parties.
Approximate cost		$ 350,000
Commitments and contingencies description	On February 18, 2022, the Company signed an outsourced manufacturing agreement with Bioana, S.A.P.I. DE C.V. The agreement is for three years, ending December 31, 2024 for a minimum order quantity of 10,000 NeuroCaps per annum. Unit cost for the NeuroCap is fixed for the first year ending December 31, 2022. The manufacturing agreement will renew annually unless terminated in writing by one of the parties.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)					1 Months Ended				3 Months Ended	12 Months Ended
	Jan. 01, 2023	Nov. 01, 2022	Sep. 01, 2022	Jun. 13, 2022	Jun. 30, 2022	Apr. 20, 2022	Mar. 31, 2022	Feb. 18, 2022	Dec. 31, 2022	Dec. 31, 2021
Subsequent Events (Details) [Line Items]
Repaid principal amount										$ 140,000
Private placement offering description										The Company received $2,000,000 of new monies through our private placement offering for convertible debt in 2022. As part of the issuance of the 2022 Notes, all of the 2021 Notes and accrued interest, as well as an additional 10% discount, was converted into shares of common stock. The holders of the 2021 Notes, in connection with their original investment, will also be entitled to warrants based on 50% coverage of their original investment amount. These warrants will have a term of four years after issuance and an exercise price of $21.25 per share.
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Repaid principal amount									$ 34,000
Interest amount									$ 14,514
Payment with accrued interest	$ 60,700	$ 49,000	$ 53,000		$ 53,000
Extension fee	2,500
Total payment	$ 63,200
Order quantity shares (in Shares)								10,000
Private placement offering description				the Company consummated the first closing of a private placement offering whereby the Company entered into a Securities Purchase Agreement (SPA), dated as of June 13, 2022 with thirteen accredited investors, pursuant to which the investors purchased from the Company, for an aggregate purchase price of $5,110,000, (i) 10% Original Issue Discount Senior Secured Convertible Debentures (the “2022 Notes”), in the principal amount of $5,659,500 and (ii) 222,311 warrants to purchase shares of common stock of the Company at the same price as the debt conversion price. In addition, 23,713 warrants were issued to the book-runner of this offering (together with the 222,311 investor warrants – the “2022 warrants”). The 2022 Notes mature on June 13, 2023 and bear interest at an annual rate of 10%. Due the issuance costs and the derivatives associated with the 2022 Notes, the Company recorded a debt discount of 4,470,289, which will be amortized using the effective interest method over the life of the loan.
Subsequent Event, Description							the Company signed an allonge amending its December 31, 2019 convertible promissory note in the original principal amount of $275,000 (the “Note”). The allonge extended the maturity date to December 31, 2022 and amended the outstanding balance and payment schedule to provide for seven monthly payments of $10,000 plus interest at the rate of 14% per annum with a final payment of $50,000 plus interest due upon maturity. The Company repaid $60,000 during the year ended 2022. On January 1, 2023, the Company further amended the Note extending the maturity date to February 15, 2023, at which time the Company will make one payment of $60,700 plus an extension fee of $2,500, for a total of $63,200.
Forecast [Member]
Subsequent Events (Details) [Line Items]
Share of common stock (in Shares)						3,380

Organization and Nature of Op_5

Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition - Merger Agreement [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Net Tangible Assets Acquired	$ (1,193,499)	$ (1,193,499)
Total Fair Value of Assets Acquired	9,919,501	11,113,000
Fair value of equity received		7,240,222
Liabilities assumed		2,978,152
Loans forgiven		605,311
Goodwill		913,184
Net working capital [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Net Tangible Assets Acquired	(1,186,622)	(1,186,622)
Right of Use Asset [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Net Tangible Assets Acquired	40,093	40,093
Lease Liability [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Net Tangible Assets Acquired	$ (46,970)	(46,970)
Brain Scientific Trade Name [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		133,000
MemoryMD Trade Name [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		533,000
Neurocap Trade Name [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		188,000
Neuro EEG Trade Name [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		11,000
Customer Relationships [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		(29,000)
NeuroEEG Developed Technology [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		35,000
NeuroCap Developed Technology [Member] | Merger Agreement [Member]
Organization and Nature of Operations (Details) - Schedule of purchase price of the acquisition [Line Items]
Total Fair Value of Assets Acquired		$ 10,242,000

Inventory (Details) - Schedul_2

Inventory (Details) - Schedule of inventory - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Inventory [Abstract]
Raw materials	$ 76,379	$ 93,190	$ 20,608
Parts		11,857	2,349
Finished goods	37,842	41,043	21,947
Total	$ 126,132	$ 146,090	$ 44,904

Prepaid Expenses and Other Cu_5

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 145,734	$ 105,900
Other prepaid expenses	11,352	46,170	$ 7,000
Lease deposits	14,378	14,378	5,000
Other assets		10
Total		$ 166,458	$ 12,000

Property and Equipment (Detai_3

Property and Equipment (Details) - Schedule of property and equipment, net - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 216,426	$ 188,961	$ 130,597
Less: Accumulated depreciation	(91,686)	(65,982)	(38,855)
Property And Equipment, net	124,740	122,979	91,742
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property And Equipment			4,164
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property And Equipment	204,143	176,678	121,433
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property And Equipment	$ 12,283	$ 12,283	$ 5,000

Intangible Assets, Net (Detai_3

Intangible Assets, Net (Details) - Schedule of allocation of purchase price of the acquisition - Merger Agreement [Member]	9 Months Ended
	Sep. 30, 2022 USD ($)
Business Acquisition [Line Items]
Net Tangible Assets Acquired	$ (1,193,499)
Total Fair Value of Assets Acquired	11,113,000
Fair value of equity received	7,240,222
Liabilities assumed	2,978,152
Loans forgiven	605,311
Goodwill	913,184
Net working capital [Member]
Business Acquisition [Line Items]
Net Tangible Assets Acquired	(1,186,622)
Right of Use Asset [Member]
Business Acquisition [Line Items]
Net Tangible Assets Acquired	40,093
Lease Liability [Member]
Business Acquisition [Line Items]
Net Tangible Assets Acquired	(46,970)
Brain Scientific trade name [Member]
Business Acquisition [Line Items]
Total Fair Value of Assets Acquired	133,000
MemoryMD trade name [Member]
Business Acquisition [Line Items]
Total Fair Value of Assets Acquired	533,000
Neurocap trade name [Member]
Business Acquisition [Line Items]
Total Fair Value of Assets Acquired	188,000
Neuro EEG trade name [Member]
Business Acquisition [Line Items]
Total Fair Value of Assets Acquired	11,000
Customer relationships [Member]
Business Acquisition [Line Items]
Customer relationships	(29,000)
NeuroCap developed technology [Member]
Business Acquisition [Line Items]
Total Fair Value of Assets Acquired	10,242,000
NeuroEEG developed technology [Member]
Business Acquisition [Line Items]
Total Fair Value of Assets Acquired	$ 35,000

Intangible Assets, Net (Detai_4

Intangible Assets, Net (Details) - Schedule of acquired intangible assets - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Average  Estimated Life	9 years
Intangible Assets Total	$ 11,113,000	$ 11,113,000
Accumulated amortization		(192,423)
Total	$ 10,343,538	10,920,577
Patent products [Member]
Finite-Lived Intangible Assets [Line Items]
Preliminary Fair Value		$ 10,277,000
Patent products [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Average  Estimated Life		3 years 3 months 18 days
Patent products [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Average  Estimated Life		15 years 4 months 24 days
Licenses and trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Preliminary Fair Value		$ 865,000
Average  Estimated Life		9 years
Customer/distribution list [Member]
Finite-Lived Intangible Assets [Line Items]
Preliminary Fair Value		$ (29,000)
Average  Estimated Life		12 years 6 months

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses (Details) - Schedule of accounts payable - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Accounts Payable [Abstract]
Trade payables	$ 1,143,649	$ 1,101,028	$ 398,155
Accrued payroll and related expenses	1,380,194	1,593,925	997,410
Accrued expenses	122,311	255,820	48,911
Customer deposits	6,882	36,491
Total	$ 2,653,036	$ 2,987,264	$ 1,444,476

Notes Payable (Details)_2

Notes Payable (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 28, 2020	Dec. 31, 2021	Sep. 30, 2022	Dec. 31, 2020	Feb. 21, 2020
Notes Payable (Details) [Line Items]
Accrued interest		$ 3,593
Outstanding principal balance		20,000
Principal amount	$ 300,000	$ 300,000
Aggregate purchase share (in Shares)	5,882
Commitment fee share (in Shares)	2,941
Additional commitment fee share (in Shares)	2,941
Net amount	$ 265,000
Fixed interest percentage	12%
debt discount	$ 300,000
Interest expense	73,151
Payments	$ 184,800
Default interest rate		24%
Warrant exercise price (in Dollars per share)		$ 102
Notes payable		$ 320,000		$ 650,000
PromissoryNotesMember
Notes Payable (Details) [Line Items]
Loaned amount					$ 20,000
Description of non-convertible promissory note		The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.

Convertible Notes Payable, Net

Convertible Notes Payable, Net (Details) - USD ($)

1 Months Ended

9 Months Ended

12 Months Ended

Dec. 30, 2021

Dec. 21, 2021

Apr. 21, 2020

Dec. 31, 2019

Sep. 30, 2022

Dec. 31, 2021

Oct. 01, 2022

May 31, 2022

Oct. 13, 2021

Oct. 01, 2021

Sep. 30, 2021

Dec. 31, 2020

Jul. 31, 2020

Convertible Notes Payable, Net (Details) [Line Items]

Principle amount

$ 900,000

$ 125,000

Outstanding principal balance

$ 9,718,915

$ 49,000

$ 53,000

Convertible Notes Payable, description.

The conversion price was set at the merger to $23.8 which is equal to 80% multiplied by the price per share used in the merger calculations.The Note contains a price-based anti-dilution provision, pursuant to which the conversion price of the Note shall be reduced upon the occurrence of certain dilutive issuances of Company securities as set forth in the Note. The conversion of the Note is also subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. In the event the Company, prior to the maturity date of the Note, issues any Security (as defined in the Note) with any term more favorable to the holder of such Security or with a term in favor of the holder of such Security that was not similarly provided to the Investor, then at the Investor’s option such term shall become a part of the Note. The Company also agreed to provide piggy-back registration rights to the investor pursuant to which the Company shall include all shares issuable upon conversion of the Note on the next registration statement the Company files with the Securities and Exchange Commission.  The Note contains events of default which, among other things, entitle the Investor to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Note. Upon the occurrence of any event of default, the outstanding balance shall immediately and automatically increase to 130% of the outstanding balance immediately prior to the event of default, and the conversion price of the Note shall be redefined to equal 65% of the lowest trade accruing during the 10 consecutive Trading Days (as defined in the Note) immediately preceding the applicable Conversion Date (as defined in the Note). Nickolay Kukekov, a director of the Company, and a third party, each has personally guaranteed the repayment of the Note. The Warrant has an exercise price of $106.25 per share (the “Exercise Price”), subject to adjustments as provided in the Warrant, and has a term of five years. The Warrant contains a price-based anti-dilution provision, pursuant to which the exercise price of the Warrant shall be reduced upon the occurrence of certain dilutive issuances of securities as set forth in the Warrant, with a corresponding increase in the number of shares underlying the Warrant if the dilutive event occurs during the first three years of the Warrant, and a cashless exercise provision. The exercise of the Warrant is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Warrant purchase shares (in Shares)

8,824

Exercise price (in Dollars per share)

$ 1

2020 Notes [Member]

Convertible Notes Payable, Net (Details) [Line Items]

Convertible notes

$ 2,400,000

Potential investment

$ 5,000,000

Interest accruing

10%

Accrued interest to common stock

120%

Notes payable amount

$ 4,119,982

$ 650,000

Accrued interest amount

$ 208,480

$ 26,766

2021 Notes [Member]

Convertible Notes Payable, Net (Details) [Line Items]

Accrued interest amount

$ 4,328,407

Convertible promissory percentage

10%

Debt assumed

1,540,508

Convertible promissory note to an investor

2,950,000

Original issuance discount

$ 2,850,000

Convertible notes payable, description

(i) the date, if any, upon which the Company’s common stock is listed for trading on the NASDAQ stock exchange (the “Uplist”), and (ii) the date that is eighteen months from the date of issuance, a warrant to purchase an amount of shares of the Company’s common stock, equal to such holder’s Warrant Share Amount. For purposes of the foregoing, a holder’s “Warrant Share Amount” means (i) if such Warrant is issued in connection with the Uplist, one half of the initial principal balance of such Holder’s Note at issuance divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the closing price for the Company’s common stock on the trading day prior to the date of the Uplist, and (ii) if such Warrant is issued otherwise than in connection with the Uplist, the initial principal balance of such Holder’s Note, divided by the lesser of (A) $34.0, and (B) and the greater of (x) $17.0 and (y) one hundred twenty percent (120%) of the volume weighted average price (“VWAP”) for the Company’s common stock over the five consecutive trading days immediately preceding the date that is eighteen months from the date of issuance. The 2021 Notes contain mandatory and voluntary conversion features as detailed in the agreement.

Assumed convertible debt [Member]

Convertible Notes Payable, Net (Details) [Line Items]

Outstanding convertible debt

$ 891,133

$ 891,133

Outstanding balance

574,133

Increasing debt

20,000

Convertible debt

337,000

2019 Note [Member]

Convertible Notes Payable, Net (Details) [Line Items]

Convertible notes payable, description

On December 30, 2021, the Company signed an allonge amending the Note extending the maturity date to April 30, 2022 and amending the outstanding balance and payment schedule to provide for two equal payments of $60,000 on March 31, 2022 and April 30, 2022. The outstanding principal balance as of December 31, 2021 was $87,000.

Original principal amount

$ 275,000

Purchase of common stock (in Shares)

1,176

Interest charged percentage

8%

Convertible Grid Notes [Member]

Convertible Notes Payable, Net (Details) [Line Items]

Principle amount

$ 125,000

Outstanding principal balance

250,000

Warrant purchase shares (in Shares)

8,824

Exercise price (in Dollars per share)

$ 68

Warrant exercise price per share (in Dollars per share)

$ 68

Debt interest rate

12%

12%

Accrued interest

$ 28,032

$ 28,032

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of operating maturity of lease liability - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Schedule of operating maturity of lease liability [Abstract]
2022	$ 21,491	$ 118,452
2023	88,325	88,325
2024	7,378	7,379
Total undiscounted finance lease payments	117,194	214,156
Less: Imputed interest		18,475
Present value of finance lease liabilities	$ 110,162	$ 195,681

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of supplemental balance sheet information related to the lease - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of supplemental balance sheet information related to the lease [Abstract]
Operating lease right-of-use asset	$ 107,617	$ 191,702
Lease liability, current portion	81,012	104,592
Lease liability, long-term	29,150	91,089
Total operating lease liability	$ 110,162	$ 195,681

Stockholders' Deficit (Detail_4

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrant Number of Shares outstanding at beginning	108,922	47,448	5,908
Warrant Weighted Average Exercise Price outstanding at beginning	$ 38.25	$ 82.45	$ 48.45
Warrant Weighted Average Remaining Contractual Term outstanding at beginning			3 years 11 months 23 days
Warrant Aggregate Intrinsic Value outstanding at beginning	$ 304,799	$ 351,125	$ 201,125
Granted Number of Shares		70,332	41,540
Granted Weighted Average Exercise Price		$ 16.15	$ 86.7
Granted Weighted Average Remaining Contractual Term		9 years 6 months 7 days	3 years 10 months 24 days
Granted Aggregate Intrinsic Value		$ 304,799	$ 150,000
Forfeited Number of Shares
Forfeited Weighted Average Exercise Price
Forfeited Weighted Average Remaining Contractual Term
Forfeited Aggregate Intrinsic Value
Exercised Number of Shares
Exercised Weighted Average Exercise Price
Exercised Weighted Average Remaining Contractual Term
Exercised Aggregate Intrinsic Value
Expired Number of Shares		(8,858)
Expired Weighted Average Exercise Price		$ 102
Expired Weighted Average Remaining Contractual Term		1 year 8 months 23 days
Expired Aggregate Intrinsic Value
Warrant Number of Shares outstanding at ending		108,922	47,448
Warrant Weighted Average Exercise Price outstanding at ending		$ 38.25	$ 82.45
Warrant Weighted Average Remaining Contractual Term outstanding at ending		6 years 10 months 6 days	3 years 4 months 20 days
Warrant Aggregate Intrinsic Value outstanding at ending		$ 304,799	$ 351,125
Warrant Number of Shares exercisable at ending		108,922
Warrant Weighted Average Exercise Price exercisable at ending		$ 27.2
Warrant Weighted Average Remaining Contractual Term exercisable at ending		6 years 10 months 6 days
Warrant Aggregate Intrinsic Value exercisable at ending		$ 304,799

Stockholders' Deficit (Detail_5

Stockholders' Deficit (Details) - Schedule of option activity - Options [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Deficit (Details) - Schedule of option activity [Line Items]
Option Number of Shares outstanding at beginning (in Shares)			11,765
Option Weighted Average Exercise Price outstanding at beginning			$ 63.75
Option Weighted Average Remaining Contractual Term outstanding at beginning	9 years 5 months 19 days		9 years 18 days
Option Aggregate Intrinsic Value outstanding at beginning (in Dollars)			$ 150,000
Granted Number of Shares (in Shares)	316,168	118,007	9,412
Granted Weighted Average Exercise Price	$ 11.05	$ 25.5	$ 63.75
Granted Weighted Average Remaining Contractual Term	5 years	9 years 9 months 25 days	10 years
Granted Aggregate Intrinsic Value		$ 196,825	$ 120,000
Forfeited Number of Shares (in Shares)	(5,602)	(909)
Forfeited Weighted Average Exercise Price	$ 17.85	$ 127.5
Forfeited Weighted Average Remaining Contractual Term	9 years 2 months 12 days	9 years 1 month 13 days
Forfeited Aggregate Intrinsic Value (in Dollars)
Exercised Number of Shares (in Shares)
Exercised Weighted Average Exercise Price
Exercised Weighted Average Remaining Contractual Term
Exercised Aggregate Intrinsic Value (in Dollars)
Expired Number of Shares (in Shares)
Expired Weighted Average Exercise Price
Expired Weighted Average Remaining Contractual Term
Expired Aggregate Intrinsic Value (in Dollars)
Option Number of Shares outstanding at ending (in Shares)		138,275	21,177
Option Weighted Average Exercise Price outstanding at ending		$ 30.6	$ 63.75
Option Weighted Average Remaining Contractual Term outstanding at ending		9 years 5 months 19 days	8 years 6 months 3 days
Option Aggregate Intrinsic Value outstanding at ending (in Dollars)		$ 196,825	$ 270,000
Option Number of Shares exercisable at ending (in Shares)	415,819	76,908
Option Weighted Average Exercise Price exercisable at ending	$ 17	$ 18.7
Option Weighted Average Remaining Contractual Term exercisable at ending	5 years 11 months 23 days	9 years 1 month 20 days
Option Aggregate Intrinsic Value exercisable at ending (in Dollars)

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Net operating loss carry forwards	$ 16,883,400	$ 12,254,418
Total amount of available losses	$ 5,239,877
Future income percentage	100%
Taxable income percentage	80%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets liabilities - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of Deferred Tax Assets Liabilities [Abstract]
Net operating loss carry forwards	$ 4,181,841	$ 2,252,985
Share-based compensation	806,997	90,110
Accrued expenses	301,422	19,009
Intangible assets	100,736	107,187
Fixed assets	(29,877)	(23,039)
Valuation allowance	(5,361,119)	(2,446,252)
Net Deferred Tax Asset

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of reconciliation statutory federal income tax	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of Reconciliation Statutory Federal Income Tax [Abstract]
Statutory federal tax rate	21%	21%
State tax expense	4.70%	4.30%
Acquired deferred tax assets	7.80%
PPP loan forgiveness	0.30%
Change in tax rate	(0.90%)
Amortization	(0.40%)
Other permanent items	(0.30%)	(0.10%)
Valuation allowance	(32.20%)	(25.20%)

Concentrations (Details)

Concentrations (Details)	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Percentage of medical devices	100%